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Abstract 
Nicotine exposure during pregnancy leads to adverse health outcomes, including compromised 
placental development. Although the molecular mechanisms remain elusive, recent studies 
identified that endoplasmic reticulum (ER) stress may underlie poor placentation. Therefore, 
we were interested in investigating the effects of nicotine exposure on the ER stress response 
in the placenta. A well-established maternal nicotine exposure rat model and Rcho-1 
trophoblast giant cell model were utilized to address the research questions. Maternal nicotine 
exposure in vivo led to elevated ER stress in association with impaired disulfide bond formation 
and hypoxia. Nicotine exposure in vitro further differentiated that ER stress may be augmented 
directly through nicotinic acetylcholine receptor activation and indirectly through nicotine-
induced hypoxia. Moreover, we relieved nicotine-induced ER stress in Rcho-1 cells in vitro 
using Tauroursodeoxycholic acid. In conclusion, this thesis provides novel mechanistic insight 
and contributes to the development of innovative therapeutic approaches to ameliorate 
nicotine-induced injury in pregnancy.  
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1 LITERATURE REVIEW  
 
 
 
 
 
 
 
 
 
 
Excerpts of this chapter have been submitted for publication and are currently in revision: 
Wong MK, Barra NG, Alfaidy NN, Hardy DB, and Holloway AC. Adverse effects of 
perinatal nicotine exposure on reproductive outcomes. Reproduction, in revision.    
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1.1 Nicotine 
1.1.1 Prevalence and concerns regarding nicotine exposure during 
pregnancy 
It is well established that cigarette smoke contains many teratogens and exposure during 
pregnancy increases the risk of adverse fetal developmental outcomes, such as placental 
abruption [1], placenta previa [2], sudden infant death syndrome [3], spontaneous abortion 
[4], stillbirth [5], low birth weight [6], and fetal growth restriction [7]. Despite increased 
awareness of these detrimental effects, approximately 10-28% of women continue to 
smoke during pregnancy worldwide [8-11]. Canada is no exception, reporting an average 
prevalence of smoking during pregnancy between 10.5-23%, with rates as high as 59.3% 
in some communities in the Northern Territories [8, 11]. Amongst those who attempt to 
quit smoking, it is suggested that only half will successfully abstain; the steep rates of 
relapse attributable in part to the highly addictive nature of nicotine [9, 12, 13]. However, 
maternal exposure to nicotine during pregnancy is not only restricted to cigarette smoking. 
Nicotine-based pharmacotherapies, such as nicotine replacement therapy (NRT), have 
been developed for smoking cessation and its usage has been considered beneficial for 
those struggling with heavy dependence [14]. NRTs are most commonly found in the form 
of chewing gums, transdermal patches, inhalers, and nasal sprays. The US FDA has 
currently assigned NRT gums under pregnancy category C (adverse effects seen in fetus in 
animal studies, but inconclusive evidence in humans; potential benefits still outweigh risks) 
and NRT transdermal patches, inhalers, and sprays are under pregnancy category D 
(adverse effects seen in human studies, but potential benefits still outweigh risks) [15]. 
Non-combustible, nicotine-containing smoking alternatives, such as e-cigarettes, have also 
garnered increased popularity within recent years especially among adults of reproductive 
age, regardless of history of cigarette use [16, 17]. E-cigarettes are perceived to be safer 
than cigarettes in that they utilize flavoured vapour and nicotine [18], but depending on the 
user’s experience and puff intervals, nicotine absorption can be similar to that of 
conventional cigarettes [19-21]. It has generally been assumed that the benefits of NRT/e-
cigarette use during pregnancy outweigh the risks, as users are able to avoid the thousands 
of other chemicals found in cigarette smoke [22, 23]; however, there is currently 
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insufficient data to verify the safety and efficacy claims of these nicotine-based products 
during pregnancy [24-26].  
Nonetheless, the usage of these nicotine-based products are still considered to be most 
strongly influenced by clinical “approval from their healthcare professional” [27].  
Alarmingly, 47% of obstetricians/gynecologists stated in a recent study to inconsistently 
screen their pregnant patients for exposure to these non-combustible tobacco products, and 
only 5% felt fully informed of the potential side-effects [28]. Furthermore, 43% of pregnant 
women reported to not even know that e-cigarettes may contain nicotine [29]. Considering 
that research is increasingly suggesting that even maternal exposure to nicotine alone may 
lead to deleterious consequences in the fetus, a more comprehensive evaluation of the 
potential effects of maternal NRT and e-cigarette use is required [30]. 
1.1.2 Nicotinic acetylcholine receptors (nAChRs) 
Nicotine exerts its effects, as first characterized by John Langley in 1905, through binding 
to nAChRs [31-33]. nAChRs are ligand-gated, transmembrane, ionotropic cation channels 
consisting of five distinct subunits (two α-, one δ-, and one β-, γ-, or ε-subunit) that interact 
in unique combinations to form different subtypes [34-36]. nAChRs have been 
demonstrated to be expressed in both neuronal and non-neuronal cell types throughout the 
body, including the placenta, and may regulate a large range of physiological functions 
(e.g., cell differentiation, migration, viability, and transmitter release) depending on 
receptor subtype and location [37-39]. nAChR binding stimulates the opening of 
nonselective cation channels, which subsequently instigates sodium influx, membrane 
depolarization, and activation of voltage-gated calcium channels [35, 40]. The resulting 
calcium influx then activates calcium-dependent kinases (e.g., protein kinase C, 
calmodulin-dependent protein kinase II, extracellular signal-regulated kinases, etc.) and 
may trigger various transcription factors (e.g., cAMP response element binding protein, 
etc.) responsible for governing the aforementioned physiological functions [41-43]. 
Endogenous agonists, such as acetylcholine, normally bind nAChRs to regulate these 
cellular pathways [35]. However, exogenous agents, such as nicotine or α-bungarotoxin, 
may also competitively or noncompetitively bind to nAChRs and exert alternative, and 
potentially pathological, effects [35].  
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1.1.3 Pharmacology of Nicotine 
1.1.3.1 Absorption and distribution 
To better appreciate the physiological impact of nAChR activation via nicotine, we must 
also review the pharmacological absorption, distribution, and metabolism of nicotine 
within the body. Nicotine (C10H14N2) can easily traverse membrane barriers due to its 
lipophilic nature and activate nAChRs within various organ systems [32]. Whole body 
nicotine distribution is rapid, occurring within seconds to minutes from exposure, with 
highest affinities in the brain, lung, liver, kidney, spleen, and skeletal muscle [44, 45]. As 
a weak base, nicotine is also susceptible to ion-trapping and accumulation in acidic bodily 
fluids/tissues – up to 2.9-fold in breast milk, placental tissue, amniotic fluid, and fetal blood 
compared to maternal serum levels, increasing risk of fetal or neonatal exposure to 
maternal nicotine [31, 46-49]. 
Consistent reports of the typical steady-state plasma nicotine concentrations in human 
smoking populations are difficult to find due to vast genetic diversity in the metabolism of 
individuals (to be discussed in greater detail later in this thesis), and between-study 
variations in mode of nicotine administration and measuring techniques used [50]. Several 
pharmacokinetic studies targeting non-pregnant smokers and/or NRT users reported ranges 
of serum nicotine concentrations between 25nM-25μM (for consistency in our 
comparisons, doses were converted from original units to molar concentration, based on 
162.23 g∙mol-1 molecular weight of nicotine) [51-55]. Fewer studies were conducted in 
pregnant human smokers/NRT users, though one report identified average serum nicotine 
concentrations of ~500nM in pregnant women who smoked approximately 20 
cigarettes/day or wore 21-mg transdermal nicotine patches [56]. Difficulty in accurately 
assessing serum nicotine levels may be due to its relatively shorter half-life (~2 hours), thus 
its metabolite, cotinine, may be measured to quantify nicotine exposure (~17 hours) [57]. 
1.1.3.2 Metabolism 
Nicotine is primarily metabolized by the liver into six metabolites, of which cotinine 
constitutes 70-80% of the product [44, 58]. The conversion of nicotine to cotinine occurs 
through the two-step C-oxidation pathway, where nicotine is first converted to nicotine-
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Δ1’(5’)-iminium ion by CYP2A6, then converted to cotinine by aldehyde oxidase [58-62]. 
Cotinine may be further metabolized into six other primary metabolites (e.g., 3’-
hydroxycotinine, etc.) [63]. Nicotine and its metabolites are eventually cleared from the 
body chiefly through renal excretion, but traces have been detected in sweat and breast 
milk [64].  
During pregnancy, the clearance of nicotine and cotinine was reported to be increased by 
60 and 140%, respectively, compared to non-pregnant women [65, 66]. Increased drug 
clearance during pregnancy is not unique to nicotine and cotinine, as similar effects were 
also seen in the metabolism of penicillin, phenytoin, and other drugs [67]. This was 
suggested to occur due to accelerated oxidation via CYP2A6 alongside faster glucuronide 
formation, though the exact mechanisms are not well understood and very unpredictable 
between individuals [66]. Interestingly, this may help explain why pregnant women were 
reported to experience decreased NRT efficacy for smoking cessation [65]. However, due 
to nicotine’s potentially harmful effects on pregnancy, caution would be warranted in 
increasing its dose and/or duration to compensate for decreased cessation efficacy [25]. 
1.1.4 Long-term health outcomes of prenatal nicotine exposure 
Since pharmacological studies have verified that nicotine directly affect various systems 
within the mother and fetus, we must next address the health consequences of exposure 
during pregnancy. There are currently no human studies available reporting the long-term 
health outcomes of adults exposed to nicotine in utero through maternal NRT or e-cigarette 
usage. However, emerging animal studies clearly demonstrate that maternal nicotine 
exposure alone may lead to deleterious long-term health outcomes in the offspring. These 
included compromised neural development [68-70], increased risk of metabolic disorders 
(e.g., increased hepatic and circulating triglycerides, impaired β-cell function and insulin 
resistance, obesity [71-80]), impaired fertility (e.g., transient testicular and epididymal 
changes, impaired ovarian function [76, 81, 82]), and poor cardiovascular and respiratory 
health (e.g., increased blood pressure, risk of hypertension, impaired alveolarization [74, 
83, 84]) (Figure 1.1).  
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Figure 1.1. Maternal exposure to nicotine alone may lead to many deleterious long-
term health outcomes in the offspring.  
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1.1.5 Short-term health and pregnancy outcomes of prenatal 
nicotine exposure 
In addition to its impact on long-term health in the offspring, maternal nicotine exposure 
may also impact short-term health and pregnancy outcomes. Findings from human studies, 
however, have generally reported minimal health effects on the offspring exposed to NRTs 
during pregnancy. A series of studies from the Smoking, Nicotine, and Pregnancy (SNAP) 
Trial Team reported no short-term postnatal health impairments from maternal NRT use 
compared to placebo after delivery and a two-year follow-up [24, 85]. Dhalwani et al. 
(2015) also did not report any change in risk of major congenital abnormalities in offspring, 
with the exception of increased risk of respiratory system anomalies [86]. Similarly, a 2012 
Cochrane review analyzing six randomized controlled trials of NRT use during pregnancy 
did not report any significant differences in rates of stillbirth, preterm labour, or low 
birthweight [24]. Yet, there are several major limitations to note across these studies: (1) 
Compliance and adherence rates were generally quite low, limiting researchers from 
consistently assessing the full effects. (2) Intervention studies relied mainly on self-report 
measures, increasing risk of bias or inaccuracy in data. (3) NRT use did not improve 
prolonged abstinence from smoking in mothers compared to placebo groups, suggesting 
that the doses provided were perhaps not strong enough to induce any effects at all, 
including effects in the offspring. Interestingly, another study found that the simultaneous 
use of more than one NRT product during pregnancy, which resulted in a higher dose of 
nicotine, was associated with mild decreases in birth weight in human offspring, suggesting 
that higher nicotine doses may indeed carry some risks for the offspring [87]. Further 
research addressing these limitations are required before conclusions may be made 
regarding the safety and efficacy of NRT and/or e-cigarette use in human pregnancy. 
The short-term and pregnancy effects of nicotine exposure in animal studies have been 
more robustly demonstrated. Nicotine exposure during pregnancy led to significant 
reductions in birth weight in rodent offspring [72, 77, 88]. This is concerning, as low 
birthweight has been associated with long-term chronic disease development (to be 
discussed in greater detail later in this chapter.) Furthermore, low birthweight in the 
offspring may implicate some degree of placental impairment, as the placenta plays a 
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critical role in governing the growth of the fetus [89-91]. Indeed, pregnant rats exposed to 
chronic nicotine injections demonstrated compromised placental development and function 
at embryonic day 15 [92], to be followed by low fetal birthweight at term [77]. 
1.2 The Placenta and its Role in Fetal Development 
The placenta is anatomically defined as the discoid-shaped, fetal-derived organ comprised 
of a fusion of fetal and maternal tissues, essential for the establishment and maintenance 
of pregnancy [93, 94]. It is important to note that the human fetus is transiently, but entirely, 
dependent on the placenta for survival through nutrient exchange, waste removal, immune 
and barrier protection, and endocrine regulation [93, 94].  
1.2.1 Human placental development 
Placental and fetal development begins with the blastocyst, an early developmental 
structure comprising the inner cell mass, blastocoel cavity, and outer trophectoderm layer 
of trophoblast cells. The blastocyst implants into the epithelial layer of the maternal uterine 
endothelium at approximately 6-7 days post-fertilization [95]. The placenta originates from 
the polar trophectoderm layer, and placentation is initiated when this endometrial-invading 
layer differentiates into the mononucleated cytotrophoblast and multinucleated 
syncytiotrophoblast layers. The syncytiotrophoblasts are responsible for initial enzyme-
mediated digestion and invasion into the maternal uterine endometrium, whereas the 
cytotrophoblasts rapidly divide and fuse to expand the syncytiotrophoblast layer [96, 97].  
Fluid-filled spaces known as syncytial lacunae develop within the syncytiotrophoblast 
layer and eventually house maternal blood as the invading syncytiotrophoblasts penetrate 
and rupture maternal capillaries. At approximately two weeks of pregnancy, finger-like 
projections known as primary chorionic villi are rapidly established, comprised of a solid 
core of cytotrophoblast cells surrounded by the outer syncytiotrophoblast layer. At day 16, 
mesenchymal cells from the underlying extraembryonic mesoderm penetrate the 
cytotrophoblast core transforming the primary chorionic villi into secondary chorionic 
villi. At day 21, these mesenchymal cells rapidly differentiate into embryonic blood vessels 
at the center of the villi, transforming the secondary chorionic villi into tertiary chorionic 
villi; this allows for greater exchange between embryonic and maternal blood. At 
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approximately five weeks of pregnancy, the cytotrophoblasts expand and breach the 
syncytiotrophoblast layer to reach the decidua basalis of the uterus. As this occurs, 
syncytial lacunae become more pronounced giving rise to the intervillous space between 
the chorionic and basal plates of the placenta, which borders the fetus and maternal 
endometrium, respectively [94]. Thirty to forty chorionic villous “trees” project from the 
chorionic plate through this intervillous space; each globular-shaped projection existing as 
an individual maternal-fetal exchange unit between the mother and fetus. Anchoring villi 
from the villous tree attach to the decidua basalis of the uterus to further secure the placenta 
and embryo, while terminal villi, richly vascularized with embryonic vessels, branch from 
the villous trees to serve as main sites of exchange [98]. Due to successful invasion and 
remodeling of spiral arteries in the maternal uterus by extravillous trophoblasts (EVTs; 
discussed in more detail below), maternal blood pools into the intervillous space from 
maternal spiral arteries, immersing the villous trees to allow for exchange to occur. 
Maternal blood then exits the intervillous space of the placenta through uterine veins to 
return to maternal circulation. Newly enriched blood within the embryonic capillaries of 
the villous trees merge at the umbilical vein to travel to the fetus; two umbilical arteries 
carry deoxygenated blood from the fetus back to the placenta to be exchanged [94].  
Perfusion of maternal blood into the intervillous space is made possible by EVTs, which 
derive from the tips of the anchoring villi and invade into the maternal myometrium to 
access and remodel the maternal uterine spiral arteries [97]. Two subpopulations of EVTs 
are responsible for invading the maternal myometrium, interstitial and endovascular 
trophoblasts. Interstitial trophoblasts invade the maternal decidual stroma and remodel the 
spiral arteries from the outside-in; whereas the endovascular trophoblasts infiltrate and 
colonize the actual vascular walls of spiral arteries, regulating blood flow to the placenta 
initially through plug formation within the lumen, and later through replacement of the 
vascular walls with trophoblast cells [99]. The EVT invasion and migration process is 
complexly regulated by a variety of factors, including growth factors [100], immune cells 
(e.g., uterine natural killer cells) [101], and many others (extensively reviewed in [102-
104]). Poor invasion and migration may contribute to the development of pregnancy 
disorders such as preeclampsia and intrauterine growth restriction (IUGR) [102].  
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Considering the indispensable role of the placenta in maintaining a healthy pregnancy, 
there remains a need to further understand the intricate physiologies and pathologies 
associated with this organ. Due to obvious ethical concerns, human studies on pregnancy 
and placentation have been limited, necessitating the development of suitable experimental 
animal and in vitro models to further the study of this multifaceted organ.  
1.2.2 The rat as a model for human placentation  
The rat serves as an appropriate model for studying many aspects of human placentation 
due to similarities in hemochorial placental structure, deep intrauterine invasion through 
both endovascular and interstitial pathways, and trophoblast-directed remodeling of uterine 
spiral arteries [105, 106]. Advantageous as well is the abundance of existing molecular 
tools to analyze rat physiology, whereas antibodies and primer sequence databases are not 
as readily available or reliable for other animal models, such as sheep, guinea pigs and 
hamsters. The mouse has also been extensively used in placental research; however, mouse 
trophoblast invasion remains far more superficial than humans, making the rat a better 
selection for in vivo studies [107, 108]. Despite the similarities, some of the major 
differences in rats compared to humans include lower number of spiral arteries, relatively 
shallow implantation, shorter gestation (21 days), and polytocous pregnancies [105]. These 
differences may limit the study of certain specific placental processes, such as 
decidualization during implantation, and prevent accurate modeling of certain pregnancy 
disorders. However, the similarities in trophoblast-directed roles [105], conserved cellular 
pathways between humans and rats [109], and ability of nicotine to cross into both species’ 
placentas [92, 110], permit usage of the rat as a model for our study. 
During rat placentation, trophoblast stem cells are established from the trophectoderm of 
the blastocyst and may derive at least five cell types (trophoblast giant (TG) cells, invasive 
trophoblasts, spongiotrophoblast cells, syncytial trophoblast cells, and glycogen cells). 
Each cell type adopts an important role in pregnancy, but the one of interest to our study 
will be the TG cell due to their large population in the rat placenta and cardinal 
involvements throughout placentation. TG cells are the first trophoblast cell lineage to 
differentiate in the early “choriovitelline” placenta, enabling uterine invasion and 
anastomosis with maternal vasculature. The mature “chorioallantoic” placenta consists of 
11 
 
the decidua, junctional, and labyrinth zones, throughout which TG cells continue to provide 
chief invasion and endocrine functions [107, 111, 112]. Similar to human extravillous 
cytotrophoblasts, rat TG cells facilitate both interstitial and endovascular invasion 
pathways in remodeling the myometrium and spiral arteries of the maternal decidua to 
perfuse the placenta [106, 113, 114]. Uterine natural killer cells and other immune cells are 
similarly suggested to direct TG cell migration and invasion [107]. The junctional zone is 
located between the decidua and labyrinth zone and consists of TG cells, 
spongiotrophoblast cells, and glycogen cells; it is mainly involved in endocrine functions 
and facilitating maternal blood to and from the placenta. The labyrinth zone is located at 
the fetal interface and consists of TG cells, syncytiotrophoblast cells, and fetal 
mesenchymal cells; it is mainly involved in maternal-fetal nutrient exchange [105, 107].  
1.2.3 In vitro models to investigate mechanisms  
In addition to in vivo animal models, numerous useful in vitro models have been developed 
to study placentation. Though in vitro systems are sometimes criticized for lack of 
translatability due to current sub-physiologically-relevant culture conditions, a major 
advantage is that the simplified setting allows for more direct investigation of underlying 
cellular mechanisms. A common in vitro approach involves the use of isolated primary cell 
cultures. Primary placental cultures may be derived from either human [115, 116] or rat 
[117] placentas, and are advantageous as they are directly sourced from the organ. 
However, procedures involved with isolation are often very tedious and stressful for the 
cells, and cultures respond poorly to repeated passaging. An alternative option is the use of 
placental cell lines derived from choriocarcinoma cells (e.g., JEG-3 [118], Rcho-1  [119]) 
or immortalized extravillous trophoblast cells (e.g., HTR-8/SVneo [120]). Placental cell 
lines are relatively easy to handle and endure longer-term culturing and repeated passaging 
[121]; however, they may exhibit phenotypic differences due to the malignancy or 
immortalization. It is essential to conduct comparative experiments in order to verify the 
appropriateness of the choriocarcinoma cell line as a model. The Rcho-1 cell line has been 
extensively studied and determined to share many similarities with true placental TG cells 
in terms of cell cycle regulation, differentiation, gene transcription profile, transport 
processes, hormone production, and others (please refer to [122] for full reference list on 
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studies). All in all, the establishment of suitable in vivo and in vitro models alongside 
clinical observations have enabled deeper study into compromised placental development 
and the consequences that may follow. 
1.2.4 The role of compromised placental development in the 
“Developmental Origins of Health and Disease” 
To better comprehend the unparalleled role of the placenta in regulating a suitable prenatal 
environment for the fetus, we must also address the importance of the prenatal environment 
in determining postnatal and long-term health. Pioneering studies by David J. Barker and 
colleagues proposed that the detrimental health outcomes seen in later life may be rooted 
in programming that occurred during an individual’s fetal life. This theory is better known 
as the “Developmental Origins of Health and Disease” [123]. One of the earliest studies 
revealed that geographical regions across England and Wales with high rates of infant 
mortality in 1921-25 strongly correlated with high rates of ischemic heart disease mortality 
later on in 1968-78 [124]. The high rates of infant mortality were attributed to nutritional 
deprivation in the area in 1921-25, and surviving individuals from these same areas who 
later developed ischemic heart disease in 1968-78 were suggested to have been particularly 
susceptible to the rich diet in later life because of their poor diet in early life. Later studies 
confirmed the association between low birth weight and the development of cardiovascular 
and metabolic disorders in adulthood [125-129]. However, it was by comparison of the 
Leningrad and Dutch famines during World War II that would serve to further advance our 
understanding of the Developmental Origins theory [130, 131]. There were no differences 
found in glucose tolerance in adults born during the 28-month Leningrad famine compared 
to those born outside the famine, whereas glucose intolerance was found in adults born 
during the 6-month Dutch famine. Correspondingly, these infants born during the long 
Leningrad famine would likely have experienced continued famine into their postnatal 
lives, whereas infants born during the short Dutch famine would have received an 
immediate reintroduction of nutrition as the famine ended, experiencing a stark 
“mismatch” between prenatal and postnatal environments [130, 131]. Therefore, it appears 
that an affluent postnatal environment is necessary to amplify the effects of a poor prenatal 
environment in later-life health outcomes. Moreover, animal models demonstrated that 
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rapid “catch-up” growth, which was induced by the return to a normal postnatal diet after 
prenatal protein restriction, led to later life development of diabetes [132]. This collectively 
revealed the crucial relationships between a poor prenatal environment, a mismatched 
affluent postnatal environment, and the adult onset of chronic diseases.  
However, many factors along with maternal diet/nutrition may also influence the quality 
of the prenatal environment and intrauterine growth of the fetus, including maternal 
hypoxia [133, 134], glucocorticoid stress levels [135], and drug exposure [26, 30]. In 
addition to maternal factors, “placental insufficiency” was found to precede many instances 
of abnormal fetal development and IUGR in humans [89-91]. Placental insufficiency will 
be defined in the context of this thesis as compromised growth, development, or function 
of the placenta, leading to an inability to meet the nutritional and other growth-related 
needs of the fetus. As demonstrated by Holloway et al. (2014), nicotine-induced placental 
insufficiency may be specifically caused by reduced growth in the decidua and junctional 
zones, impaired markers of cell proliferation and vascularization in the labyrinth zone, and 
inhibition of trophoblast cell differentiation, invasion, and migration [92]; however, the 
underlying cellular mechanisms have yet to be fully elucidated. Several mechanisms have 
been proposed to underlie placental insufficiency at the cellular level, including increased 
oxidative stress [136, 137] and inflammation [138, 139]. Another mechanism that was 
more recently proposed to underlie placental insufficiency is an intracellular protein 
folding disturbance known as endoplasmic reticulum (ER) stress [140-143].  
1.3 ER Stress and the Unfolded Protein Response (UPR) 
The ER is the organelle primarily responsible for protein synthesis, folding and maturation, 
and secretion within the cell [144]. Protein folding capacity may be affected by many 
factors, such as calcium levels in the ER, disulfide bond formation, asparagine (N)-
glycosylation, and ATP/glucose availability [109]. Calcium plays an important role in 
protein folding by both directly interacting with nascent proteins and enabling the activity 
of ER-resident calcium-binding chaperones, such as calreticulin [145]. However, ER 
calcium stores fluctuate rapidly through the inositol 1,4,5-triphosphate/ryanodine receptors 
and sarco/endoplasmic reticulum calcium-ATPases (SERCAs) during intracellular 
signaling, which may influence protein folding efficiency [146]. Successful co- and post-
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translational protein modifications also depends on disulfide bond formation [147]. 
Occurring through a series of redox reactions, disulfide bonds are initially introduced by 
protein disulfide isomerase (PDI) through thiol oxidation. ER oxidoreductase (Ero1-Lα/β) 
subsequently reoxidizes PDI to continue the redox relay [148]. Various alternative ER 
oxidoreductases, VKORC1 [149], GPx-7/8 [150], QSOX1 [151], have also been 
discovered to potentially assist with PDI reoxidation, or may directly oxidize thiols of 
nascent proteins. ER oxidases are then reoxidized by FAD, and finally by a terminal 
electron acceptor such as oxygen [147]. Therefore, adequate oxygen levels and a proper 
redox environment are essential in the formation of disulfide bonds and protein maturation 
[109, 147]. Alongside disulfide bond formation, N-glycosylation is another key 
modification required in most proteins. This process involves covalent oligosaccharide 
attachment to the asparagine residue of nascent proteins, upon which they may then be 
associated with lectin chaperones, calnexin and/or calreticulin, to undergo further folding 
[152, 153]. Moreover, sufficient ATP and glucose availability are required at various steps 
during many of these processes (i.e., ATP required for SERCA-directed calcium influx to 
ER, and glucose required for ATP generation and synthesis of oligosaccharide for N-
glycosylation [154, 155]). Properly matured proteins may then be exported to the Golgi 
complex for additional alterations, or to the cytosol to fulfill their functions within the cell.  
ER stress is classically defined as the perturbation of any of these functions leading to an 
accumulation of misfolded or unfolded proteins within the ER lumen [109]. Human studies 
revealed a strong association between ER stress and placental insufficiency [141, 142]. 
Yung et al. (2008) found significantly increased ER stress in growth-restricted placentas 
from IUGR pregnancies compared to control placentas from normal pregnancies [141]. 
Women who newly migrated to high altitude regions (3100m), which is known to induce 
placental insufficiency and fetal IUGR due to decreased oxygen availability, also exhibited 
placental growth restriction and ER stress compared to control sea-level placentas [142]. 
Experimental induction of ER stress using the drug tunicamycin, which inhibits N-linked 
glycosylation to cause protein misfolding, decreased proliferation in JEG-3 and JAR 
trophoblast cells in vitro [141]. Kawakami et al. (2014) further explicated these findings 
by demonstrating that chronic tunicamycin-induced ER stress in pregnant mice in vivo 
leads to compromised placentation and low birth weight offspring [156]. Mice that were 
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especially vulnerable to ER stress, due to genetically-modified elevations in basal protein 
translation, also demonstrated placental insufficiency and low birth weight offspring [143]. 
Altogether, these studies strongly suggest that augmented placental ER stress may underlie 
placental insufficiency, leading to IUGR in the offspring.  
The UPR aims to alleviate ER stress and restore homeostasis by activating a series of 
transcriptional and translational quality-control events that increase protein folding 
capacity and decrease incoming protein traffic [109]. Additional quality-control 
mechanisms also exist to further relieve ER stress in more dire situations, such as ER-
associated degradation (ERAD) and autophagy. The ERAD pathway retrotranslocates 
terminally misfolded proteins from the ER lumen into the cytosol where they are 
ubiquitinated for proteasomal degradation [157, 158]. Severe accumulation of misfolded 
protein aggregates may further initiate autophagy of the ER, which involves sequestering 
of the targeted organelle and associated cytoplasm into membrane-bound compartments 
for lysosomal degradation [159, 160]. However, for the purposes of this thesis, we will 
focus our review on the three canonical pathways of the UPR.  
Each UPR pathway is governed by an ER-resident transmembrane protein transducer, 
including activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1), and 
protein kinase-like ER kinase (PERK). Though the sensory mechanisms underlying the 
activation of the UPR in response to ER stress remain somewhat unclear, Ron and Walter 
(2007) have compiled the current evidence into three possible theoretical models [160]. 
The first model, termed the direct recognition model, proposes that each ER stress 
transducer (ATF6, IRE1, and PERK) directly interacts and senses misfolded/unfolded 
proteins via their luminal domains, though the evidence is mainly  drawn from structural 
studies on IRE1 [161, 162]. The second model, termed the indirect recognition model, 
proposes that glucose-regulated protein 78 (BiP/GRP78), an ER chaperone protein, 
normally remains bound to the three transducers to maintain inactivity. In the presence of 
ER stress, BiP disassociates from the transducers to chaperone the misfolded/unfolded 
proteins, and thus initiates activation of the UPR pathways [163-165]. The third model, 
termed the hybrid recognition model, acknowledges the valid culmination of data from 
both theories and proposes that luminal binding and BiP disassociation are mutually 
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involved in activating the UPR [160]. Regardless of the mode of sensing stress, each UPR 
transducer is known to differentially respond to distinct forms and causes of ER stress (e.g., 
inhibition of N-linked glycosylation, dysregulation of calcium homeostasis, etc.) [166], 
thus there is insult-dependent specificity involved in the activation of each UPR pathway.  
1.3.1 ATF6 pathway of the UPR 
In the first pathway of the UPR, ATF6 translocates to the Golgi bodies to become cleaved 
from 90 to 50 kDa by site-1 and site-2 proteases. Cleaved ATF6 may then enter the nucleus 
to facilitate transcription of genes involved in protein folding/chaperoning (e.g., Grp78), 
ERAD, and lipid biogenesis [109, 167, 168]. Two ubiquitously-expressed isoforms of 
ATF6 exist in eukaryotes, ATF6α/β, and both are involved in the same processes [169]. 
However, ATF6α is a rapidly-degraded, potent transcriptional activator of ER stress 
response genes [170], whereas ATF6β is a stably-expressed, weak activator [171]. Due to 
these properties, ATF6β is suggested to hinder ATF6α-mediated gene transcription, and 
balanced expression of the two isoforms are important for fine-tuning the ATF6-dependent 
ER stress response [171, 172]. In experimental models, Atf6α-knockout mice were more 
susceptible to hyperinsulinemia after high-fat diet feeding [173], and increased ATF6 
pathway activation was seen in β cells of diabetes-modeling Akita mice [174], revealing a 
potential role in diabetes. ATF6 was also shown to synergistically upregulate transcription 
of X-box binding protein 1 (Xbp1) and C/EBP-homologous protein (Chop) alongside the 
other two UPR transducers [175, 176], and may share various downstream gene targets 
with XBP1 [177], demonstrating cross-talk between the pathways.  
1.3.2 IRE1 pathway of the UPR 
In the second pathway of the UPR, IRE1 homodimerizes and undergoes 
autophosphorylation at its cytoplasmic domain [178, 179]. Phosphorylation of IRE1 
activates an endoribonuclease domain which unconventionally splices Xbp1 mRNA 
transcript. Translation of spliced Xbp1 transcript yields active XBP1, a transcription factor 
that enters the nucleus to up-regulate the transcription of genes involved in protein 
folding/chaperoning, ERAD, lipid biogenesis, and autophagy [180-182]. The IRE1 
pathway was previously reported to play essential roles in pancreatic development and 
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function [183-185], neurological disorders [186], and angiogenesis in tumour formation 
[187]. Furthermore, two isoforms of IRE1 exist in higher eukaryotes, where IRE1α is 
ubiquitously expressed [188], and IRE1β is uniquely expressed in the gut [189]. Ire1α 
knockouts in mice led to embryonic lethality due to dysfunctional placental labyrinth 
organization, which is crucial for maternal-fetal exchange. Interestingly, embryonic 
viability was maintained when Ire1α knockout was conditionally restricted only to the 
embryo without affecting the placenta, implicating an integral role for IRE1α in placenta-
dependent survival [180]. Ire1β knockout did not affect viability in mice, though it 
increased susceptibility to dextran sodium sulfate-induced inflammatory bowel disease 
compared to controls [190]. 
In an alternate pathway known as the regulated IRE1-dependent decay (RIDD) pathway, 
IRE1 also functions to rapidly degrade a select subset of mRNAs under conditions of ER 
stress in order to decrease the availability of transcripts for translation [191, 192]. The 
RIDD pathway has been shown to carry important roles in inflammation/immunity [193] 
and lipid metabolism [194]. 
1.3.3 PERK pathway of the UPR 
In the third pathway of the UPR, PERK homodimerizes and autophosphorylates its 
cytoplasmic domain. Phosphorylated PERK further phosphorylates eukaryotic initiation 
factor (eIF) 2 at Ser51 of the α-subunit (eIF2α) [195]. Normally, eIF2, GTP and methionyl-
initiator tRNA comprise the ternary complex involved in protein translation. The ternary 
complex mediates the binding of methionyl-initiator tRNA with the 40S ribosomal subunit 
to initiate translation, alongside various other eIFs and ribosomal complexes [196]. When 
the initiation codon AUG of the targeted mRNA is detected by methionyl-initiator tRNA, 
the GTP coupled to eIF2 is hydrolyzed to GDP, as catalyzed by eIF5, to assist with binding 
of 60S ribosomal subunit to the initiation complex. eIF2-GDP is then released, allowing 
for the remainder of translation to occur. eIF2B catalyzes the exchange of GDP for GTP 
on eIF2 to permit the formation of new ternary complexes for successive rounds of 
translation [197]. However, phosphorylation of eIF2α by PERK inhibits disassociation 
from eIF2B, thus preventing subsequent eIF2B-catalyzed GDP-GTP exchange from 
occurring. Therefore, initiation of translation is attenuated for most mRNA transcripts 
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during ER stress, reducing incoming protein traffic into the ER lumen [196, 198]. 
Phosphorylated eIF2α, however, paradoxically elevates the translation of select transcripts 
involved in mediating ER stress, such as Atf4, Chop, and Grp78 [199-204]. Acute 
activation of the PERK pathway was previously reported to play a protective role in organs 
involved with high protein secretory activity, such as the pancreas or placenta [143, 205]. 
Furthermore, PERK may be involved in hypoxic adaptation of tumour cells via 
translational regulation of proangiogenic genes, implicating a potential role in cancer [206].  
In addition to PERK, there are three other known kinases that may phosphorylate eIF2α 
depending on the insult. Double-stranded RNA-activated inhibitor (DAI), also known as 
Protein Kinase RNA (PKR), is activated in the presence of viral infection [207]. Heme-
regulated inhibitor (HRI) is activated during iron or heme deficiency, arsenite, or 
osmotic/heat shock [208]. General control nonderepressible 2 (GCN2) is activated during 
amino acid starvation or UV irradiation [209, 210]. These pathways are collectively known 
as the Integrated Stress Response, commonly converging at eIF2α phosphorylation to 
regulate translation and related downstream responses under diverse stress conditions.  
1.3.4 The consequences of chronic ER stress and UPR activation 
If ER stress persists and the UPR remains chronically activated, several downstream 
apoptotic pathways may become amplified to initiate cell death. One of the major pathways 
of ER stress-induced cell death involves mitochondrial apoptosis through the pro-apoptotic 
BCL2 family members (i.e., BCL2-Associated X protein (BAX), BCL2-Antagonist/Killer 
(BAK), BCL2-Interacting Mediator of cell death (BIM), p53-Upregulated Modulator of 
Apoptosis (PUMA), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA)). 
Though the apoptotic involvement of BCL2 family member proteins in the placenta 
remains unclear, they have been well-studied in various other cell types. Firstly, ER stress 
may lead to down-regulation of anti-apoptotic B-cell CLL/lymphoma 2 (BCL2) 
expression, allowing BAX/BAK to translocate and perforate the mitochondrial membrane 
for cytochrome c release and apoptosis [211]. Indeed, tunicamycin and thapsigargin, a 
selective SERCA inhibitor that causes ER stress, down-regulated Bcl2 expression and led 
to increased cell death in several fibroblast cell lines [212, 213]. Also, overexpression of 
Bcl2 [212, 213] and/or double knock-out of Bax/Bak [211] protected against ER stress-
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induced cell death. Secondly, ER stress may lead to increased activation of BCL2-
homology 3 (BH3)-only proteins (e.g., BIM, PUMA, NOXA, etc. [214]). BIM was shown 
to be a critical initiator of apoptosis after tunicamycin and thapsigargin-induced ER stress 
in various cell types (thymocytes, macrophages, renal tubular epithelial cells, breast cancer 
derived cells, and kidney epithelial cells), and Bim knockout increased survival during ER 
stress [214]. ER stress may also lead to increased expression of PUMA and/or NOXA, 
which were demonstrated to play important roles in ER stress-induced apoptosis in mouse 
embryonic fibroblasts [215] and primary cortical neurons [216]. This may occur through 
either p53-dependent or -independent mechanisms during ER stress [215, 216]. Some other 
mediators of ER stress-induced cell death include the caspase pathway (caspase 12, 9, and 
3), tribbles homolog 3, and death receptor 5, amongst others [217].  
Importantly, most ER stress-related apoptotic pathways are understood to be triggered by 
CHOP, a transcription factor regulated by ATF4 and phosphorylated eIF2α of the PERK 
pathway [204, 218]. Chop deletions/knockouts attenuated BIM and PUMA induction [214, 
216], restored Bcl2 expression [213], increased cell survival during ER stress in various 
cell types/organs [219-222], improved glucose regulation and beta cell mass in diabetic 
mouse models [223], and reduced neuronal cell loss in ischemic brain injury [224]. In 
summary, ER stress and UPR-mediated apoptosis and cell death, as predominantly 
mediated by CHOP, may lead to placental insufficiency, and ultimately compromise fetal 
development (Figure 1.2).  
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Figure 1.2. Maternal insults may augment ER stress and induce activation of the 
UPR. Chronic activation of the UPR may lead to downstream apoptosis or other cytotoxic 
effects, potentially underlying placental insufficiency.  
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1.4 Rationale, Hypothesis, and Objectives 
1.4.1 Rationale and Hypothesis 
Therefore, the rationale for this Master’s thesis was founded upon two major premises 
(Figure 1.3):  
(1) Maternal nicotine exposure in pregnancy leads to increased hypoxia [92, 110, 225] 
and placental insufficiency [92]. 
(2) Both hypoxia and placental insufficiency have been demonstrated to be strongly 
associated with ER stress [141, 143, 147, 156, 226]. 
Therefore, we hypothesize that nicotine exposure leads to augmented ER stress in the 
rat placenta in vivo and in vitro. 
 
 
 
Figure 1.3. Schematic diagram illustrating the rationale of our study, summarizing what 
associations are currently known (connecting lines) and what we are interested in 
investigating (arrow). 
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1.4.2 Objectives  
The long-term objective of this study is to characterize the nicotine-induced ER stress 
response in the rat placenta. In other words, this study aims to elucidate the impact of 
maternal nicotine exposure on placental development and function through the 
augmentation of ER stress and the UPR. By identifying the cellular mechanisms underlying 
the adverse outcomes of nicotine exposure, we may contribute to the development of 
innovative therapeutic interventions to alleviate the deleterious outcomes of nicotine 
exposure on placental development – ultimately benefiting both maternal and fetal health 
during pregnancy.  
The short-term objectives are:  
(i) To investigate the effects of maternal nicotine exposure on ER stress in the rat 
placenta in vivo. 
(ii) To investigate the direct and indirect effects of nicotine exposure on ER stress in 
rat placental trophoblast giant cells in vitro.  
(iii) To ameliorate nicotine-induced ER stress and UPR activation in rat placental 
trophoblast giant cells in vitro using Tauroursodeoxycholic acid (TUDCA). 
Objective (i) will be addressed in Chapter 2 of this thesis. Objectives (ii) and (iii) will be 
addressed in Chapter 3 of this thesis.  
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2 MATERNAL NICOTINE EXPOSURE LEADS TO 
IMPAIRED DISULFIDE BOND FORMATION AND 
AUGMENTED ENDOPLASMIC RETICULUM 
STRESS IN THE RAT PLACENTA 
 
 
 
 
 
 
 
 
A version of this chapter has been previously published: Wong, M.K., Nicholson, C.J., 
Holloway, A.C., and Hardy, D.B. (2015) Maternal nicotine exposure leads to impaired 
disulfide bond formation and augmented endoplasmic reticulum stress in the rat placenta. 
PLoS One 10(3): p. e0122295. 
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2.1 Introduction 
Despite increased awareness and education, approximately 10-28% of women reported to 
continue smoking during pregnancy [1-4]. Cigarette smoke contains many teratogens, and 
exposure during pregnancy increases the risk of adverse pregnancy and neonatal outcomes, 
including placental abruption, placenta previa, sudden infant death syndrome, spontaneous 
abortion, stillbirth, low birth weight, and fetal growth restriction [5-11]. Although many 
pregnant women want to quit smoking, recent studies suggest that only 50% successfully 
abstain from smoking during pregnancy, due in part to the highly addictive nature of 
nicotine [12, 13]. 
Nicotine replacement therapies (e.g., nicotine patches and gums) were developed to assist 
with smoking cessation while concurrently allowing the smoker to avoid the thousands of 
chemicals in cigarette smoke [14]. Although nicotine replacement therapies are often 
considered to be safer than smoking, there is still great concern regarding the effects of 
nicotine on fetal and postpartum health (please refer to [15] for a review).  
Due to the lipid-soluble nature of nicotine, it easily traverses membrane barriers to enter 
the placenta, where it can bind to many subtypes of nicotinic acetylcholine receptors 
(nAChR) previously reported to be expressed in human and rat placental 
syncytiotrophoblasts, cytotrophoblasts, Hofbauer cells, visceral yolk sac epithelium, and 
amniotic epithelium [16, 17]. Emerging animal studies demonstrate that nicotine alone 
during pregnancy can lead to compromised placental and fetal development, with many 
detrimental health outcomes in the offspring [18-24]. Furthermore, nicotine exposure in 
utero results in low birth weight pups, implicating placental insufficiency [25-27]. 
Specifically, nicotine in utero led to compromised placental development in pregnant rat 
dams (e.g., compacted decidual and junctional zones, decreased labyrinth vascularization 
and cell proliferation, increased placental hypoxia, and impaired trophoblast 
differentiation) at embryonic day 15, prior to any observable fetal growth deficiencies [17]. 
Given that compromised placental development is a strong predictor of fetal growth 
restriction in humans, elucidation of the underlying mechanisms would be therapeutically 
beneficial for offspring exposed to nicotine in utero [28]. However, to date, mechanisms 
linking maternal nicotine exposure to compromised placental function remain elusive.  
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Recent studies have suggested that endoplasmic reticulum (ER) stress, the perturbation of 
ER homeostasis due to the accumulation of misfolded or unfolded proteins, plays a critical 
role underlying compromised placentation [29-33]. The unfolded protein response (UPR) 
activates to alleviate the stress and restore ER homeostasis through three major signaling 
pathways governed by activating transcription factor 6 (ATF6), inositol-requiring enzyme 
1α endoribonuclease (IRE1α), and protein kinase-like endoplasmic reticulum kinase 
(PERK) [34-36]. However, if the ER remains severely debilitated, C/EBP-homologous 
protein/Gadd153 (CHOP) activates downstream apoptosis [37, 38], which has been 
associated with compromised placental growth both in vivo and in vitro [31, 39]. Since the 
ER is the primary site of protein synthesis and maturation within the cell, prolonged 
disturbance of its function through ER stress could negatively impact essential signaling 
and transport function in the placenta (e.g., Vegf and Glut-1 expression) [29, 40-43]. 
Moreover, one of the key processes underlying protein maturation and folding within the 
ER lumen is the disulfide bond formation of nascent proteins through protein thiol 
oxidation, and deterrence of its function has been demonstrated to augment ER stress [40, 
44-46]. It is important to note that due to high protein secretory activity in the placenta, 
low-moderate basal levels of UPR activation may occur even under normal physiological 
conditions; however, chronic pathological augmentation may rear consequences in 
placental development [29, 33, 47].  
Nicotine is known to induce vasoconstriction in placental and umbilical vasculature, thus 
restricting oxygen and nutrient (e.g., amino acids) supply [48, 49]. Interestingly, hypoxia 
and low amino acid supply have been demonstrated to both hinder disulfide bond formation 
and induce ER stress in vitro [50-54]. Exposure to cigarette smoke or nicotine has also 
been shown to cause ER stress in several tissue/cell types, but little is known about the 
mechanisms underlying maternal nicotine exposure in vivo on ER stress and disulfide bond 
formation in the developing placenta [55-61]. Therefore, the aim of this study was to 
determine whether maternal nicotine exposure in vivo leads to augmented placental ER 
stress and impaired disulfide bond formation in the rat placenta. 
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2.2 Materials and Methods 
2.2.1 Experimental model 
All animal experiments were approved by the Animal Research Ethics Board at McMaster 
University in accordance with the guidelines of the Canadian Council for Animal Care. 
Nulliparous female Wistar rats (200–250 g, Harlan, Indianapolis, IN, USA) were randomly 
assigned to receive daily subcutaneous injections of either saline (vehicle) (n=6) or nicotine 
bitartrate (1 mg/kg, Sigma-Aldrich) (n=5) for 14 days prior to mating and during 
pregnancy. This dose has previously resulted in maternal and neonatal serum cotinine 
concentrations similar to either moderate female smokers and/or low-dose nicotine 
replacement therapy users [24, 62-64]. Mating (embryonic day (e) 0) was confirmed by the 
presence of sperm in a vaginal flush. At necropsy (e15) whole placentas were harvested, 
immediately flash-frozen in liquid nitrogen, and stored at -80 °C until molecular analyses 
were performed. Each placenta used in molecular analyses was taken from a different dam.  
2.2.2 RNA extraction and Real Time-Polymerase Chain Reaction 
(RT-PCR) 
Total RNA was extracted from homogenized whole placentas using TRIzol reagent 
(Invitrogen). Chloroform (Sigma-Aldrich) was added to the solution, and then centrifuged 
at 12,500rpm. Supernatant was transferred to a fresh tube with an equal volume of 
isopropanol (Sigma-Aldrich) and centrifuged again at 12,500rpm. Total RNA was then 
collected from the pellet and dissolved in DEPC-treated water. Deoxyribonuclease I, 
Amplification Grade (Invitrogen) was added to the RNA to digest contaminating single- 
and double-stranded DNA. Four μg of RNA were reverse-transcribed to cDNA using 
random hexamers and Superscript II Reverse Transcriptase (Invitrogen). Primer sets 
directed against gene targets of interest were designed through National Center for 
Biotechnology Information’s primer designing tool and generated via Invitrogen Custom 
DNA Oligos (Table 1). Quantitative analysis of mRNA expression was performed via RT-
PCR using fluorescent nucleic acid dye SsoFast EvaGreen supermix (BioRad) and BioRad 
CFX384 Real Time System. The cycling conditions were 95 °C for 10 min, followed by 43 
cycles of 95 °C for 15 sec and 60 °C for 30 sec and 72 °C for 30 sec. The cycle threshold 
was set so that exponential increases in amplification were approximately level between 
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all samples. Relative fold changes were calculated using the comparative cycle times (Ct) 
method, normalizing all values to the geometric means of three housekeeping genes (β-
Actin, 18S, and Gapdh). Suitable housekeeping genes were determined using algorithms 
from GeNorm [65], Normfinder [66], BestKeeper [67], and the comparative ΔCt method 
[68] to provide an overall ranking of the most stable housekeeping genes (available online 
at http://www.leonxie.com/referencegene.php). (Please refer to Appendix I, Supplemental 
Figure 1 to see all mRNA targets normalized to individual housekeeping genes). Given all 
primer sets had equal priming efficiency, the ΔCt values for each primer set were calibrated 
to the experimental samples with the lowest transcript abundance (highest Ct value), and 
the relative abundance of each primer set compared with calibrator was determined by the 
formula 2ΔΔCt, in which ΔΔCt was the normalized value. 
2.2.3 Xbp1 splicing assay 
Quantitative analysis of Xbp1 mRNA splicing was performed as previously described [69]. 
Briefly, primers were designed to span the unique exon-exon border formed by 
unconventional IRE1 splicing to target spliced Xbp1 mRNA. Primers were also designed 
to target total Xbp1 mRNA (Table 1). Results were normalized to the geometric means of 
three housekeeping genes (β-Actin, 18S, and Gapdh), and then a ratio of spliced to total 
Xbp1 was taken to quantify the splicing of Xbp1. 
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Table 2.1. Forward and reverse sequences for the primers used for quantitative 
Real-Time PCR. 
Gene Forward Reverse  GenBank/ 
Reference 
Atf6 GGATTTGATGCCTTGGG
AGTCAGAC 
ATTTTTTTCTTTGGAGT
CAGTCCAT 
NM_001107
196.1 
Xbp1 GAGCAGCAAGTGGTGG
AT 
TCTCAATCACAAGCCC
ATG 
NM_001004
210.2 
Spliced 
Xbp1 
GAGTCCGCAGCAGGTG GCGTCAGAATCCATGG
GA 
[69] 
Grp78 AACCCAGATGAGGCTG
TAGCA 
ACATCAAGCAGAACCA
GGTCAC 
NM_013083
.2  
Atf4 CCTGACTCTGCTGCTTA
TATTACTCTAAC 
ACTCCAGGTGGGTCAT
AAGGTTTG 
NM_024403
.2 
Chop CCAGCAGAGGTCACAA
GCAC 
CGCACTGACCACTCTGT
TTC 
NM_001109
986.1 
Prdx4 TCCTGTTACAGACTGAA
GCTTTGC 
GTGATCTGCGACCGAA
ACCC 
NM_053512
.2 
Gpx-7 CCTGCCTTCAAATACCT
AACCC 
TGTAATACGGGGCTTG
ATCTCC 
NM_001106
673.1 
Vkorc1 GCTGGTGGAGCATGTGT
TAGG 
CAACGTCCCCTCAAGC
AACC 
NM_203335
.2 
Qsox1 AGCCACTGCCCTAGATG
TACC 
TGAGGCCTGCGTTTAGT
TCC 
NM_001109
898.1 
Bax AGGATCGAGCAGAGAG
GATGG 
GACACTCGCTCAGCTTC
TTGG 
NM_017059
.2 
Bcl-2 TGTGGATGACTGAGTAC
CTGAACC 
CAGCCAGGAGAAATCA
AACAGAGG 
NM_016993
.1  
β-Actin CACAGCTGAGAGGGAA
AT 
TCAGCAATGCCTGGGT
AC 
NM_031144 
 
18S TTGCTGATCCACATCTG
CTGG 
ATTGCCGACAGGATGC
AGAA 
M11188.1 
Gapdh GGATACTGAGAGCAAG
AGAGAGG 
TCCTGTTGTTATGGGGT
CTGG 
NM_017008
.4 
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2.2.4 Protein extraction and Western Blot 
Whole placentas were homogenized in RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Nonidet P40, 0.25% C24H39NaO4, supplemented with phosphatase 
inhibitors (20 mM NaF, 40mM Na-pyrophosphate, 40mM Na3VO4, 200mM β-
glycerophosphate disodium salt hydrate), and a protease inhibitor cocktail (Roche)). The 
solution was sonicated at 30% amplitude for 5 sec total, 1 sec per pulse. It was then mixed 
in a rotator for 10 min at 4 °C and centrifuged at 300g for 15 min at 4 °C. The supernatant 
was collected and centrifuged at 16000g for 20 min at 4 °C. The resulting supernatant was 
collected as the total cellular protein extract and quantified by colorimetric DC protein 
assay (BioRad). Loading samples were prepared with fresh total cellular protein extract 
(avoiding repeated freeze-thaw cycles), NuPAGE LDS Sample Buffer (4X) (Invitrogen), 
NuPAGE Reducing Agent (10X) (Invitrogen), and deionized water, and heated at 70 °C 
for 10 min to denature the proteins. Proteins (20μg/well) were separated by size via gel 
electrophoresis in gradient polyacrylamide gels (Novex), and transferred onto 
polyvinylidene difluoride membrane (Millipore). Membranes were blocked in 1x Tris-
buffered saline-Tween 20 buffer with 5% non-fat milk (blocking solution), and then probed 
using primary antibodies of the protein targets of interest, all diluted in the blocking 
solution (Table 2). Secondary antibodies were used to detect the species-specific portion 
of the primary antibody, all diluted in the blocking solution (Table 3). Immuno-reactive 
bands were visualized using SuperSignal West Dura Chemiluminescent Substrate (Thermo 
Scientific). Relative band intensity was calculated using BioRad ImageLab software and 
normalized to the quantified protein levels of β-Actin for each respective membrane, as β-
Actin served as an appropriate housekeeping gene for this study. 
2.2.5 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5 software. All results were 
expressed as means of normalized values ± SEM. The significance of the differences 
(p<0.05) between normalized mean values was then evaluated using the two-tailed, 
nonparametric Mann-Whitney test. 
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Table 2.2. Western Blot primary antibodies, dilutions used in experiments, and 
company and catalogue information. 
Antibody name Source Dilution Company (#Catalogue) 
KDEL (GRP78) (10C3)  Mouse 
monoclonal 
1:300 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-58774) 
ATF6  Mouse 
monoclonal 
1:600 Novus Biologicals, Oakville, ON, 
Canada (NBP1-40256) 
Phospho-PERK 
(Thr980) (16F8)  
Rabbit 
monoclonal 
1:500 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3179) 
PERK (D11A8)  Rabbit 
monoclonal 
1:500 Cell Signaling Technology Inc., 
Danvers, MA, USA (#5683) 
Phospho-eIF2α (Ser51) 
(119A11) 
Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3597) 
eIF2α  Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#9722) 
CREB-2 (ATF4) (C-20)  Rabbit 
polyclonal 
1:5000 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-200) 
CHOP (D46F1) Rabbit 
monoclonal 
1:500 Cell Signaling Technology Inc., 
Danvers, MA, USA (#5554) 
ERO1-Lα  Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3264) 
PDI (C81H6) Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3501) 
VKORC1 (D-17) Rabbit 
polyclonal 
1:500 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-54456-
R) 
Quiescin Q6 (QSOX1) 
(G-12) 
Goat 
polyclonal 
1:500 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-160084) 
GPx-7 (S-12)  Goat 
polyclonal 
1:500 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-160062) 
Caspase-3 (8G10) Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#9665) 
Caspase-6 Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#9762) 
Caspase-7 (D2Q3L) Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#12827) 
Lamin A/C (4C11) Mouse 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#4777) 
BAX Rabbit 
polyclonal 
1:500 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-493) 
BCL-2 Rabbit 
polyclonal 
1:100 Abcam Inc., Toronto, ON, Canada 
(#ab7973) 
HIF1α Rabbit 
polyclonal 
1:2000 Novus Biologicals, Oakville, ON, 
Canada (NB100-479) 
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GCN2 Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3302) 
β-Actin Mouse 
monoclonal 
1:50000 Sigma-Aldrich Co., St. Louis, MO, 
USA Canada (#A3854) 
Table 2.3. Western Blot secondary antibodies, dilutions used in experiments, and 
company and catalogue information. 
Antibody name Dilution Company (#Catalogue) 
Donkey Anti-Rabbit IgG (H+L) 1:10000 Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA (#711-001-003) 
Donkey Anti-Mouse IgG (H+L) 1:5000 Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA (#715-001-003) 
Donkey Anti-Goat IgG (H+L) 1:5000 Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA (#705-001-003) 
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2.3 Results 
2.3.1 Maternal nicotine exposure leads to augmented ER stress 
and unfolded protein response activation in embryonic day 
15 placenta 
To determine the presence of ER stress in nicotine-exposed placenta, we assessed mRNA 
and protein levels of the main players involved in the three branches of the UPR (ATF6, 
IRE1α, and PERK) via Real-Time PCR and Western blot, respectively. Activation of the 
UPR indicates the presence of ER stress [35]. With respect to the ATF6 branch of the UPR, 
the steady-state mRNA levels of Atf6 were found to be significantly elevated in e15 
nicotine-treated placentas compared to controls (p<0.05), however, the protein levels of 
active ATF6(p50) remained unaltered (Figure 2.1A-C). To determine the activation of the 
IRE1α branch, splicing of its downstream target, Xbp1 mRNA, was measured and found 
to be unaltered (Figure 2.1D). However, nicotine exposure led to activation of the PERK 
branch of the UPR as demonstrated through significantly increased ratios of 
phosphorylated PERK [Thr980]: total PERK protein levels in nicotine-exposed placentas 
compared to controls at e15 (p<0.05, Figure 2.1A, E). Nicotine exposure also led to 
significantly increased ratios of phosphorylated eukaryotic initiation factor (eIF) 2α 
[Ser51]: total eIF2α protein levels in the placenta (p<0.05), suggesting global protein 
translation attenuation (Figure 2.1A, F). 
Since activation of the PERK pathway of the unfolded protein response was demonstrated, 
we decided to next investigate the expression of its potential downstream targets, ATF4, 
GRP78, and CHOP. ATF4 protein levels were significantly elevated in e15 nicotine-
exposed placentas compared to controls (p<0.01) with unchanged steady-state mRNA 
levels (Figure 2.2A-C). GRP78 protein levels were also significantly elevated in nicotine-
exposed placentas (p<0.05) with unchanged mRNA levels (Figure 2.2A, D-E), revealing 
post-transcriptional ER-stress-related increases in protein expression. However, nicotine 
exposure led to increased expression of CHOP (p<0.05), indicating prolonged ER stress 
and potential activation of ER-stress-related apoptotic pathways in e15 placentas (Figure 
2.2A, F-G). Collectively, these results confirm the presence of augmented ER stress and 
unfolded protein response activation of the PERK pathway in nicotine-treated placentas. 
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Figure 2.1. The effect of maternal nicotine exposure on the three branches of the 
unfolded protein response (ATF6, IRE1α, PERK) in e15 rat placentas. Protein and 
mRNA levels of targets of interest were determined via Western blot and RT-PCR, 
respectively. (A) Specific targeted protein bands as detected by respective antibodies via 
Western blot. (B) Atf6 mRNA levels. (C) ATF6 protein levels. (D) mRNA levels of spliced 
Xbp1, unspliced Xbp1, and ratio of spliced: unspliced Xbp1. (E) Protein levels of p-PERK, 
PERK, and ratio of p-PERK:PERK. (F) Protein levels of p-eIF2α, eIF2α, and ratio of p-
eIF2α:eIF2α. All protein levels were expressed as means normalized to β-Actin ± SEM 
(n=5-6/group). All mRNA levels were expressed as means normalized to the geometric 
mean of three stable housekeeping genes (β-Actin, 18S, and Gapdh) ± SEM (n=5-6/group). 
*, Significant difference (p<0.05). **, Significant difference (p<0.01). 
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Figure 2.2. Nicotine exposure leads to activation of downstream targets in the PERK 
branch of the unfolded protein response in e15 rat placentas. Protein and mRNA levels 
of targets of interest were determined via Western blot and RT-PCR, respectively. (A) 
Specific targeted protein bands as detected by respective antibodies via Western blot. (B) 
Atf4 mRNA levels. (C) ATF4 protein levels. (D) Grp78 mRNA levels. (E) GRP78 protein 
levels. (F) Chop mRNA levels. (G) CHOP protein levels. All protein levels were expressed 
as means normalized to β-Actin ± SEM (n=5-6/group). All mRNA levels were expressed 
as means normalized to the geometric mean of three stable housekeeping genes (β-Actin, 
18S, and Gapdh) ± SEM (n=5-6/group).*, Significant difference (p<0.05). **, Significant 
difference (p<0.01). 
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2.3.2 The effects of nicotine-induced activation of CHOP on 
downstream apoptotic pathways 
Due to elevated expression of CHOP in nicotine-exposed placentas, we next wanted to 
determine the expression of downstream apoptotic targets, pro-apoptotic Bax and anti-
apoptotic Bcl-2, which are known to synergistically orchestrate apoptosis [37, 71]. To 
assess the level of apoptotic activation, the ratio of Bax:Bcl-2 mRNA levels were 
quantified; however, we found no significant difference between groups (Figure 2.3A, B). 
There was a slight increase in BAX protein and decrease in BCL-2 protein in nicotine-
exposed placentas compared to controls, however, neither the markers nor their ratio 
reached statistically significant differences (Figure 2.3A, C). Maternal nicotine exposure 
also did not alter the mRNA levels of Bim or Puma (Appendix I, Supplemental Figure 2).  
2.3.3 Maternal nicotine exposure does not induce caspase-
mediated apoptosis 
To further investigate the severity of the ER stress, we measured another major ER stress-
related apoptotic pathway, the caspase-mediated apoptosis pathway. We found no 
significant differences in the protein levels of cleaved caspase-3, 6, 7, nor their substrate 
Lamin A, between control and nicotine-exposed placentas at e15 (Figure 2.4).  
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Figure 2.3. The effect of maternal nicotine exposure on downstream CHOP-mediated 
apoptotic pathways. Protein and mRNA levels of targets of interest were determined via 
Western blot and RT-PCR, respectively. (A) Specific targeted protein bands as detected by 
respective antibodies via Western blot. (B) mRNA levels of Bax, Bcl-2, and ratio of Bax: 
Bcl-2. (C) Protein levels of BAX, BCL-2, and ratio of BAX: BCL-2. All protein levels 
were expressed as means normalized to β-Actin ± SEM (n=5-6/group). All mRNA levels 
were expressed as means normalized to the geometric mean of three stable housekeeping 
genes (β-Actin, 18S, and Gapdh) ± SEM (n=5-6/group). 
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Figure 2.4. The effect of maternal nicotine exposure on downstream caspase-mediated 
apoptotic pathways. Protein levels of targets of interest were determined via Western blot. 
(A) Specific targeted protein bands as detected by respective antibodies via Western blot. 
(B) Cleaved caspase-3 protein levels. (C) Cleaved caspase-6 protein levels. (D) Cleaved 
caspase-7 protein levels. (E) Cleaved Lamin A protein levels. All protein levels were 
expressed as means normalized to β-Actin ± SEM (n=5-6/group). 
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2.3.4 Maternal nicotine exposure down-regulates expression of 
protein disulfide isomerase and ER oxidoreductases 
In order to elucidate the underlying mechanisms of nicotine-induced ER stress in the 
placenta, we further examined disulfide bond formation, a process intimately connected 
with ER homeostasis and known to cause ER stress when compromised [52]. Specifically, 
we were interested in looking at the effects of nicotine on expression of the key isomerase 
and oxidoreductases that carry out disulfide bond formation. Protein disulfide isomerase 
(PDI) mediates protein folding by introducing disulfide bonds to nascent proteins through 
thiol oxidation. ER oxidoreductase, ERO1-Lα/β, will then subsequently reoxidize PDI to 
continue the redox relay [40, 44, 45]. Interestingly, PDI protein levels were found to be 
significantly decreased in nicotine-exposed placentas at e15 (p<0.05, Figure 2.5A, B). In 
contrast, the main ER oxidoreductase, ERO1-Lα, demonstrated no significant change 
between treatment groups (Figure 2.5A, C). 
These results provoked further exploration of the expression of alternative ER 
oxidoreductases (e.g., PRDX4, GPx-7, VKORC1, and QSOX1) recently found to be 
involved in PDI reoxidation and/or direct thiol oxidation of nascent proteins [72-77]. Real-
time PCR revealed decreases in the steady-state mRNA levels of Gpx-7, Vkorc1 (p<0.05) 
and Qsox1 (p<0.05, Figure 2.6A, B, D, F). Additionally, QSOX1 was significantly 
decreased at the protein level in nicotine-treated placentas compared to the controls 
(p<0.05, Figure 2.6A, G). 
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Figure 2.5. Nicotine decreases PDI expression in e15 rat placentas. Protein levels of 
targets of interest were determined via Western blot. (A) Specific targeted protein bands as 
detected by respective antibodies via Western blot. (B) PDI protein levels. (C) ERO1-Lα 
protein levels. All protein levels were expressed as means normalized to β-Actin ± SEM 
(n=5-6/group). *, Significant difference (p<0.05). 
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Figure 2.6. The effect of maternal nicotine exposure on various ER oxidoreductases 
in e15 rat placentas. Protein and mRNA levels of targets of interest were determined via 
Western blot and RT-PCR, respectively. (A) Specific targeted protein bands as detected by 
respective antibodies via Western blot. (B) Gpx-7 mRNA levels. (C) GPx-7 protein levels. 
(D) Vkorc1 mRNA levels. (E) VKORC1 protein levels. (F) Qsox1 mRNA levels. (G) 
QSOX1 protein levels. All protein levels were expressed as means normalized to β-Actin 
± SEM (n=5-6/group). All mRNA levels were expressed as means normalized to the 
geometric mean of three stable housekeeping genes (β-Actin, 18S, and Gapdh) ± SEM 
(n=5-6/group). *, Significant difference (p<0.05). 
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2.3.5 Maternal nicotine exposure increases markers of hypoxia 
and amino acid deprivation 
Given that oxygen is the final electron acceptor in post-translational disulfide bond 
formation [52], we next investigated whether hypoxia was induced by nicotine exposure 
by measuring placental protein levels of hypoxia-inducible factor (HIF) 1α [78, 79]. 
Western blot revealed that HIF1α protein levels were significantly elevated in e15 nicotine-
treated placentas compared to the controls (p<0.05, Figure 2.7A, B). We were also 
interested in exploring whether additional insults induced by the vasoconstrictive effects 
of nicotine were present (e.g., low amino acid supply) [48]. General control non-
depressible 2 (GCN2) is a protein kinase that responds to amino acid starvation by up-
regulating transcription factors (e.g., GCN4) to mediate nutrient deprivation. GCN2 also 
acts as an alternative kinase to phosphorylate eIF2α alongside PERK to attenuate protein 
translation [80, 81]. Western blot revealed that GCN2 protein levels were strongly elevated 
in e15 nicotine-treated placentas compared to the controls (p<0.01, Figure 2.7A, C). 
 
 
Figure 2.7. Nicotine-induced vasoconstriction leads to both hypoxia and reduced 
amino acid supply in e15 placenta. Protein levels of targets of interest were determined 
via Western blot. (A) Specific targeted protein bands as detected by respective antibodies 
via Western blot. (B) HIF1α protein levels. (C) GCN2 protein levels. All protein levels 
were expressed as means normalized to β-Actin ± SEM (n=5-6/group). *, Significant 
difference (p<0.05). **, Significant difference (p<0.01). 
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2.4 Discussion 
In the current study, we have demonstrated that nicotine exposure in pregnant rats leads to 
augmented ER stress in the e15 placenta. We were interested in selecting a time-point 
during pregnancy when nicotine exposure was previously shown to cause structural and 
morphological aberrations in the rat placenta, prior to exhibiting any observable fetal 
growth deficit [17, 25]. Given that ER stress and placental insufficiency were observed to 
precede human intrauterine growth restriction [26, 27, 29, 31, 33], the presence of 
augmented ER stress exhibited in e15 nicotine-exposed rat placentas reveal a potential 
mechanism through which nicotine may cause adverse placental and fetal outcomes in 
pregnant mothers who are smoking or undergoing nicotine replacement therapy.  
An elegantly conducted study by DuRose et al. (2006) revealed intrinsic differences 
between the three UPR pathways (ATF6, IRE1α, and PERK) in their abilities to sense and 
recognize distinct types of ER perturbations [82]. We demonstrated that maternal nicotine 
exposure selectively activates the PERK unfolded protein response pathway in e15 rat 
placentas. Increases in the steady-state levels of Atf6 mRNA proposes possible 
involvement of the ATF6 branch, however, the lack of change in the protein levels and 
transcript levels of downstream target (e.g., Grp78), do not strongly support this at this 
particular time-point. Activation of PERK induces phosphorylation of eIF2α, which 
attenuates global protein translation to reduce the incoming protein load [83-85]. 
Phosphorylated eIF2α also paradoxically elevates translation of mRNA transcripts with 
conserved upstream open reading frames, such as Atf4, which was demonstrated through 
unchanged Atf4 mRNA levels, but significantly increased protein levels in our nicotine-
treated placentas compared to controls [86-88]. Interestingly, GRP78 protein levels were 
also found to be significantly up-regulated in nicotine-treated placentas compared to 
controls, amidst unchanged mRNA levels. Grp78 mRNA transcription is more commonly 
regulated by ATF6 and IRE1α branches of the UPR; however, various post-transcriptional 
mechanisms (e.g., alternative translation initiation due to eIF2α phosphorylation) have 
been demonstrated to independently regulate protein levels of GRP78 in the presence of 
ER stress regardless of transcript levels [89, 90].  
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CHOP, which may be up-regulated by ATF4 and/or phosphorylated eIF2α, is known to 
amplify various downstream apoptosis pathways (e.g., down-regulation of anti-apoptotic 
BCL-2 expression, translocation of BCL-2-associated X protein (BAX) to mitochondria to 
amplify death pathway, etc.) [38, 71, 91-95]. However, the minimal changes seen in the 
ratio of BAX: BCL-2, Bim, and Puma expression despite significantly increased CHOP 
expression perhaps suggests an early stage of CHOP activation in e15 nicotine-exposed 
placentas, when downstream apoptosis have not yet been fully elicited. The other 
possibility is that although CHOP is involved in the translocation of BAX to the 
mitochondria, it may not be involved in up-regulating the transcription of Bax [94]. The 
lack of change seen in other caspase markers further indicates the absence of nicotine 
effects on these specific apoptosis pathways at this particular time point. However, the 
expression of placental genes previously found to be influenced by nicotine (e.g., up-
regulation of Vegf and down-regulation of Glut-1) are also altered in the same manner by 
tunicamycin (a known inducer of ER stress), without any reported activation of apoptosis 
[17, 29, 96, 97]. This collectively suggests that the structural and morphological aberrations 
in nicotine-exposed placentas may be due to the ER stress-induced alterations in gene 
expression caused by nicotine, instead of pathological apoptosis [17]. Therefore, the 
nicotine-induced unfolded protein response at e15 may possibly be attempting to avoid 
apoptosis by re-establishing some manner of sub-optimal placental homeostasis to adapt to 
the ER stress experienced. 
Activation of the unfolded protein response also reveals possible dysfunction of protein 
maturation. Disulfide bond formation is critical for successful co- and post-translational 
modifications during protein maturation, and impairment is known to lead to ER stress [35, 
98]. Traditionally, PDI and/or QSOX1 expression increases during hypoxia, tunicamycin 
or thapsigargin-induced ER stress to further assist with protein folding and disulfide bond 
formation [99-102]. PDI has also been found to be up-regulated in the lungs of chronic 
smokers, perhaps as a protective response against the oxidative damage of chronic cigarette 
smoke exposure [103-105]. However, down-regulation of mRNA transcripts of essential 
isomerases and oxidoreductases in disulfide bond formation (e.g., Vkorc1, Qsox1) was 
seen in the nicotine-exposed rat placentas at e15. Protein levels were also seen to be 
significantly down-regulated in a few markers (e.g., PDI, QSOX1), though to a lesser 
64 
 
degree compared to the change in mRNA levels. It is possible that these transcripts initially 
down-regulated by nicotine are being subsequently stabilized at the protein level by the 
unfolded protein response, which seeks to post-transcriptionally up-regulate their protein 
levels in the presence of ER stress, as seen in previous studies [99-105]. This may explain 
the milder changes seen in protein levels of VKORC1 and QSOX1, despite strong 
decreases in their transcript levels. Interestingly, cigarette smoke has recently been 
demonstrated to also lead to excessive posttranslational oxidation of PDI, abating its 
functionality in the formation of disulfide bonds [60]. Given that inhibition of PDI is also 
known to disrupt protein folding and augment ER stress, it may be stipulated that the 
nicotine-induced down-regulation of PDI and other oxidoreductases at e15 may still be 
contributing in part to the augmentation of ER stress, despite the adaptive efforts of the 
unfolded protein response to stabilize their protein levels [46]. In addition to the 
impairment on disulfide bond formation, the influence that nicotine may have on nicotinic 
acetylcholine receptor-directed calcium signaling may also influence ER homeostasis and 
stress activation (please refer to section 1.1.2 for background on nicotinic acetylcholine 
receptor activation.) Regardless, more studies must be conducted on the effects of nicotine 
on calcium signaling in UPR activation and PDI and oxidoreductase regulation to further 
address these speculations. 
It is noteworthy that increased expression of HIF1α, alongside previously reported 
increases in CA-IX expression, jointly reveals hypoxia in nicotine-exposed placentas [17, 
78, 79]. The increase in hypoxia may be due to nicotinic antagonism of nAChR α9, which 
induces vasoconstriction of placental vasculature to reduce oxygen supply [48, 49]. 
Koritzinsky et al. (2013) recently identified oxygen as the terminal electron acceptor in 
post-translational disulfide bond formation, further implicating the impairment of protein 
maturation in hypoxia-induced ER stress [52]. Additionally, vasoconstriction is known to 
reduce nutrient and amino acid supply to the placenta [48]. Nicotine has also been 
documented to depress amino acid transport system A and block acetylcholine-mediated 
nutrient delivery in trophoblasts, collectively hindering the maternal transport of many 
essential amino acids to the feto-placental unit [106-108]. Significantly increased 
expression of GCN2 indeed reveals amino acid starvation in nicotine-exposed placentas 
[80, 81]. Furthermore, GCN2 is an alternative kinase of eIF2α and may be partially 
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responsible for its phosphorylation alongside PERK to cooperatively initiate an integrated 
stress response to hypoxia/ER stress and amino acid starvation [109]. However, future 
research is directed to further investigate the relationships between low amino acid supply 
and impaired disulfide bond formation. 
In summary, this study has demonstrated that nicotine alone can induce ER stress and 
evoke an integrated stress response in the rat placenta, as revealed through PERK- and 
GCN2-activation of the p-eIF2α-ATF4-CHOP axis (summarized in Figure 2.8). Recent 
studies have demonstrated the induction of ER stress via super-physiological nicotine 
dosages or cigarette smoke [55-61]; however, our study was the first to induce ER stress 
in the rat placenta through an in vivo model of maternal nicotine exposure using 
physiological nicotine dosages. Furthermore, we provide novel insight by demonstrating 
this in association with impairment of the disulfide bond formation pathway, as shown 
through nicotine-induced down-regulation of PDI and QSOX1 expression and increased 
hypoxia. By elucidating that maternal nicotine exposure is linked to placental ER stress 
and impaired disulfide bond formation, this may contribute to the development of more 
efficacious interventions (e.g., Tauroursodeoxycholic acid to relieve ER stress [110]). 
More importantly, given that nicotine alone exerts severe effects on placental function, and 
consequently, on fetal and postnatal health, this study further implicates that greater caution 
is required for women considering nicotine replacement therapy for smoking cessation in 
pregnancy. 
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Figure 2.8. Proposed schematic of the effect of nicotine on ER stress and the unfolded 
protein response in the e15 placenta. Pathways affected by nicotine are indicated by the 
darkened arrows and boxes. In summary, nicotine exposure was shown to augment ER 
stress and activate the unfolded protein response in the e15 placenta. Activation was most 
prominent in the PERK branch and was demonstrated in association with impaired 
disulfide bond formation. Nicotine is proposed to impair disulfide bond formation through 
direct or indirect down-regulation of PDI and other oxidoreductases. Disulfide bond 
formation is further impaired through increased hypoxia as caused by nicotine-induced 
vasoconstriction. Additionally, up-regulation of GCN2 suggests amino acid starvation and 
activation of the integrated stress response to further phosphorylate eIF2α. However, the 
lack of BAX and caspase activation seen at e15 suggests that the nicotine-induced ER stress 
response may possibly be attempting to avoid apoptosis by re-establishing some manner of 
sub-optimal placental homeostasis to adapt to the ER stress experienced. 
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3.1 Introduction 
Nicotine exposure during pregnancy remains a rampant issue worldwide. Recent studies 
reported that approximately 10-28% of pregnant women across various countries continued 
to engage in cigarette smoking [1-3], but exposure to nicotine can also occur through 
nicotine replacement therapies (NRTs), e-cigarettes, and other forms of non-combustible 
tobacco products [4-6]. The risk of nicotine exposure through NRTs or e-cigarettes during 
pregnancy had been long overlooked in comparison to the known hazards of traditional 
cigarette smoking. However, findings from animal studies revealed many deleterious long-
term health consequences in the offspring exposed to nicotine alone in utero, demanding a 
careful reevaluation of the impact of maternal nicotine exposure [6, 7]. 
Maternal nicotine exposure leads to structural, morphological, and functional defects in rat 
placentation in vivo [8]. The lipid-soluble nature of nicotine allows it to rapidly traverse 
past membrane barriers into the placenta where it competes with endogenous acetylcholine 
for binding to nAChRs. Many nAChR subtypes are expressed in both human and rat 
placentas, and nAChRs in rat placental trophoblast cells were previously demonstrated to 
be responsive to a large range of nicotine concentrations (10-3 to 10-9 M) [8-10]. Nicotine 
can impair trophoblast cell differentiation, migration, and invasion in vitro in a dose-
dependent manner, revealing a potential direct effect of nicotine exposure that may be 
responsible for compromised placental development [11]. Alternatively, nicotine can also 
lead to vasoconstriction in placental vasculature in vivo, which may induce hypoxia in 
placental cells, revealing a potential indirect effect of nicotine exposure on poor placental 
development [10, 12]. Nonetheless, the mechanisms by which these different nicotine-
induced effects compromise placentation have yet to be elucidated. 
Augmented endoplasmic reticulum (ER) stress was recently suggested to underlie the 
detrimental phenotype seen in nicotine-exposed placentas [13]. ER stress is generally 
defined as the cellular perturbation of ER homeostasis leading to the accumulation of 
misfolded or unfolded proteins [14]. The unfolded protein response (UPR) is activated to 
alleviate the stress through various signaling pathways that either decreases global protein 
translation or increases protein folding capacity [15]. However, under prolonged ER stress 
and UPR activation, the cell will activate downstream apoptosis, which has been well-
78 
 
associated with compromised placental growth both in vivo and in vitro [16-20]. Due to 
the broad scope of effects that nicotine can elicit in the placenta that may potentially 
contribute to ER stress in vivo, we were interested in further investigating the potential 
underlying mechanisms at the cellular level. 
The rat serves as a suitable model for studying placentation due to its similarities to humans 
in hemochorial placental structure, deep intrauterine invasion through both endovascular 
and interstitial pathways, close analogy of cell types, and trophoblast-directed remodeling 
of uterine spiral arteries [21, 22]. During rat placentation, trophoblast stem cells are 
established from the blastocyst and may give rise to at least five cell types [21]. The one 
of interest to our study will be the trophoblast giant (TG) cell due to their large population 
in the rat placenta, cardinal involvements in early establishment through uterine invasion 
and anastomosis of maternal blood supply, and later maintenance of a healthy pregnancy 
through key endocrine roles in local and systemic physiological adaptations [23-25]. Given 
that nicotine negatively impacts TG cell function and differentiation [8], and ER stress 
underlies poor placentation [16, 19, 20], we were interested in determining the direct and 
indirect effects of nicotine exposure on ER stress in placental TG cells. 
Consequently, we were also interested in investigating whether we could relieve nicotine-
induced ER stress via treatment with Tauroursodeoxycholic acid (TUDCA), an 
endogenous taurine-conjugated ursodeoxycholic bile acid produced by intestinal bacteria 
[26]. Exogenous application of TUDCA has previously relieved ER stress and stabilized 
UPR activation in several cell and tissue types [27-29], but its efficacy as a therapeutic 
agent in the placenta and on nicotine-induced ER stress have yet to be examined.  
Therefore, this study aims to investigate: (1) the direct effect of nicotine exposure through 
nAChR activation on ER stress, (2) the indirect effect of nicotine exposure through hypoxia 
on ER stress, and (3) the capacity of TUDCA to prevent nicotine-induced ER stress. We 
hypothesize that nicotine exposure will directly induce ER stress in Rcho-1 TG cells 
through nAChR activation, the indirect effects of nicotine exposure through placental 
hypoxia will also induce ER stress, and there will be an interaction effect between nicotine 
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and hypoxia to jointly augment placental ER stress. We further hypothesize that TUDCA 
will prevent nicotine-induced ER stress and UPR activation. 
3.2 Materials and Methods 
3.2.1 Experimental model 
Rcho-1, a cell line derived from rat choriocarcinoma, was used to study the effects of 
nicotine exposure on ER stress in placental TG cells. Rcho-1 cells may be maintained in 
either proliferative stem cell-like or differentiated TG cell state based on the culture 
conditions [30]. Rcho-1 trophoblast stem (TS) cells were plated at 1.5 x 106 cells/mL and 
cultured at 37oC in 95% room air/5% CO2 [30]. Proliferation was maintained by growing 
Rcho-1 TS cells in RPMI-1640 media supplemented with 20% fetal bovine serum. At 80-
90% confluency (after 3 days of proliferation), TG cell differentiation was induced by 
switching to NCTC-135 media supplemented with 1% horse serum. Removal of essential 
nutrients in the fetal bovine serum halted proliferation and encouraged differentiation into 
TG cells. NCTC-135 media was used as it was experimentally determined to provide better 
pH regulation and decreased toxicity during differentiation [30]. 
3.2.2 RNA extraction and Real Time-Polymerase Chain Reaction 
(RT-PCR) 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen). Chloroform 
(Sigma-Aldrich) was added to the solution, and then centrifuged at 12,500rpm. Supernatant 
was transferred to a fresh tube with an equal volume of isopropanol (Sigma-Aldrich) and 
centrifuged again at 12,500rpm. Total RNA was then collected from the pellet and 
dissolved in DEPC-treated water. Deoxyribonuclease I, Amplification Grade (Invitrogen) 
was added to the RNA to digest contaminating single- and double-stranded DNA. Four μg 
of RNA were reverse-transcribed to cDNA using random hexamers and Superscript II 
Reverse Transcriptase (Invitrogen). Primer sets directed against gene targets of interest 
were designed through National Center for Biotechnology Information’s primer designing 
tool and generated via Invitrogen Custom DNA Oligos (Table 3.1). Quantitative analysis 
of mRNA expression was performed via RT-PCR using fluorescent nucleic acid dye 
SsoFast EvaGreen supermix (BioRad) and BioRad CFX384 Real Time System. The 
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cycling conditions were 95 °C for 10 min, followed by 43 cycles of 95 °C for 15 sec and 60 
°C for 30 sec and 72 °C for 30 sec. The cycle threshold was set so that exponential increases 
in amplification were approximately level between all samples. Relative fold changes were 
calculated using the comparative cycle times (Ct) method, normalizing all values to the 
geometric mean of two housekeeping genes (β-Actin and Gapdh). Suitable housekeeping 
genes were determined using algorithms from GeNorm [31], Normfinder [32], BestKeeper 
[33], and the comparative ΔCt method [34] to provide an overall ranking of the most stable 
housekeeping genes (available online at http://www.leonxie.com/referencegene.php). 
Given all primer sets had equal priming efficiency, the ΔCt values for each primer set were 
calibrated to the average of all control Ct values, and the relative abundance of each primer 
set compared with calibrator was determined by the formula 2ΔΔCt, in which ΔΔCt was the 
normalized value. 
Table 3.1. Forward and reverse sequences for the primers used for RT-PCR. 
Gene Forward Reverse GenBank/ 
Reference 
Pl-1 TGACTTTGACTCTTTCGG
GCT 
GCTCTGAATACACCGAG
AGCG 
[35] 
Pgf GTGAGTATGCTGAGCCT
AAGGG 
AGACCTTACAAGACATG
GATTCCC 
NM_053595.
2 
Hand1 GCGAAAGCAAGCGGAAA
AGG 
CAGCCAGTGCGTCCTTT
AATCC 
NM_021592.
2 
β-Actin CACAGCTGAGAGGGAAA
T 
TCAGCAATGCCTGGGTA
C 
NM_031144 
Gapdh GGATACTGAGAGCAAGA
GAGAGG 
TCCTGTTGTTATGGGGTC
TGG 
NM_017008.
4 
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3.2.3 Protein extraction and Western Blot 
Cells were homogenized in RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Nonidet P40, 0.25% C24H39NaO4, supplemented with phosphatase inhibitors 
(20 mM NaF, 40mM Na-pyrophosphate, 40mM Na3VO4, 200mM β-glycerophosphate 
disodium salt hydrate), and a protease inhibitor cocktail (Roche)). The solution was 
sonicated at 30% amplitude for 5 sec total, 1 sec per pulse. It was then mixed in a rotator 
for 10 min at 4 °C and centrifuged at 16000g for 20 min at 4 °C. The resulting supernatant 
was collected as the total cellular protein extract and quantified by colorimetric DC protein 
assay (BioRad). Loading samples were prepared with fresh total protein extract (avoiding 
repeated freeze-thaw cycles), NuPAGE LDS Sample Buffer (4X) (Invitrogen), NuPAGE 
Reducing Agent (10X) (Invitrogen), and deionized water, and heated at 70 °C for 10 min 
to denature the proteins. Proteins (20μg/well) were separated by size via gel electrophoresis 
in gradient polyacrylamide gels (Novex), and transferred onto polyvinylidene difluoride 
membrane (Millipore). Membranes were blocked in 1x Tris-buffered saline-Tween 20 
buffer with 5% non-fat milk (blocking solution), and then probed using primary antibodies 
of the protein targets of interest, diluted in the blocking solution (Table 3.2). Secondary 
antibodies were used to detect the species-specific portion of the primary antibody, diluted 
in the blocking solution (Table 3.3). Immuno-reactive bands were visualized using 
SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific). Relative band 
intensity was calculated using BioRad ImageLab software and normalized to the quantified 
total protein on each respective membrane, as determined through Amido black staining.  
3.2.4 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5 software. All results were 
expressed as means of normalized values ± SEM. All experiments were replicated four 
times (n=4). The significance of the differences (p<0.05) between normalized mean values 
were then evaluated using either one-way ANOVA followed by Tukey’s post-test, or two-
way ANOVA followed by Bonferroni’s post-test to compare individual and interactive 
effects of treatments where appropriate. 
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Table 3.2. Western Blot primary antibodies, dilutions used in experiments, and 
company and catalogue information. 
Antibody name Source Dilution Company (#Catalogue) 
BiP (GRP78) Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3183) 
P-PERK (Thr981) Rabbit 
polyclonal 
1:800 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA (#sc-32577) 
PERK (D11A8) Rabbit 
monoclonal 
1:500 Cell Signaling Technology Inc., 
Danvers, MA, USA (#5683) 
Phospho-eIF2α (Ser51) 
(119A11) 
Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#3597) 
eIF2α Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#9722) 
CHOP (D46F1) Rabbit 
monoclonal 
1:500 Cell Signaling Technology Inc., 
Danvers, MA, USA (#5554) 
Caspase-3 (8G10) Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#9665) 
HIF1α Rabbit 
polyclonal 
1:2000 Novus Biologicals, Oakville, ON, 
Canada (NB100-479) 
Phospho-mTOR 
(Ser2448) 
Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#2971) 
mTOR Rabbit 
polyclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#2972) 
Akt1 Rabbit 
monoclonal 
1:1000 Cell Signaling Technology Inc., 
Danvers, MA, USA (#2938) 
β-Actin Mouse 
monoclonal 
1:50000 Sigma-Aldrich Co., St. Louis, MO, 
USA Canada (#A3854) 
 
Table 3.3. Western Blot secondary antibodies, dilutions used in experiments, and 
company and catalogue information. 
Antibody name Dilution Company (#Catalogue) 
Donkey Anti-Rabbit IgG 
(H+L) 
1:10000 Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA (#711-001-003) 
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3.3 Results 
3.3.1 Verification of Rcho-1 TG cell differentiation 
TG cells differentiation was confirmed either through phase contrast microscopy of distinct 
morphological traits (i.e., multiple nuclei, large cell body) (Figure 3.1A) and/or through 
quantitative measurement of prolactin-I (Pl-1) mRNA levels via RT-PCR, which are 
uniquely expressed by TG cells (Figure 3.1B). 
 
 
Figure 3.1. Different methods used to detect the presence of differentiated Rcho-1 TG 
cells. (A) Phase contrast microscopic images (10X) throughout 10 days of differentiation. 
(B) mRNA levels of Pl-1 as measured through RT-PCR. White triangles identify several 
representative TG cells.  
  
84 
 
3.3.2 Nicotine exposure dose-dependently increased PERK 
activation in Rcho-1 placental TG cells 
After 10 days of differentiation, Rcho-1 TG cells were treated with various doses of 
nicotine (0.1-100μM) for 6 or 24 hours. The nicotine doses encompassed (and surpassed, 
at 100μM) the average serum concentrations of nicotine (25nM-25μM) previously reported 
in pharmacokinetic studies of cigarette smoking and/or NRTs [36-41]. The 6 hour time-
point ensured detection of rapid protein phosphorylation events (e.g., phosphorylation of 
PERK, eIF2α) and the 24 hour time-point allowed detection of later changes in protein and 
mRNA expression. Activation of the UPR indicated the presence of ER stress [14]. 
Increasing nicotine concentration (0.1-100μM) led to a dose-dependent activation of the 
PERK branch of the unfolded protein response in Rcho-1 TG cells. This was demonstrated 
through the increasing ratio of phosphorylated (P)-PERK:PERK protein levels with 
increasing nicotine dose at 6 hours, reaching significantly elevated levels at 10μM and 
100μM nicotine exposure compared to control (p<0.05, p<0.001, respectively; Figure 
3.2A, B). At 24 hours, the ratio of P-PERK:PERK protein levels were still significantly 
changed with different nicotine doses, but increases were no longer dose-dependent 
(p<0.01; Figure 3.2A, C). 
Downstream of PERK, a similar response to nicotine was seen in the phosphorylation of 
eIF2α. At 6 hours, the ratio of P-eIF2α:eIF2α dose-dependently increased with nicotine 
concentration, reaching significantly increased levels at 100μM nicotine compared to 
control (p<0.01; Figure 3.3A, B). However, protein levels were no longer significantly 
different from one another at 24 hours (Figure 3.3A, C). Protein levels of CHOP, a 
transcription factor downstream of P-eIF2α involved in activating ER stress-related 
apoptotic pathways during chronic ER stress [42-48], remained unaltered at 6 hours. Levels 
appeared to be trending towards an increase at 24 hours, but remained non-significantly 
changed (Figure 3.3A, D-E). 
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Figure 3.2. The effect of various doses of nicotine (0.1-100μM) on phosphorylation of 
PERK after 6 and 24 hours in Rcho-1 TG cells.  (A) Specific targeted protein bands as 
detected by respective antibodies via Western blot. (B) Protein levels of P-PERK, PERK, 
and ratio of P-PERK:PERK at 6 hours and (C) 24 hours of nicotine exposure. All arbitrary 
values were expressed as means normalized to Amido Black ± SEM. All experiments were 
performed in quadruplicates (n=4). Significant differences between treatment groups as 
determined by one-way ANOVA (1WA) indicated by ** (p<0.01) or *** (p<0.001). 
Different letters represent means that are significantly different from one another according 
to Tukey’s post-test (p<0.05). Non-significant differences (p>0.05) indicated by n.s.  
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Figure 3.3. The effect of various doses of nicotine exposure (0.1-100μM) on UPR 
targets downstream of PERK after 6 and 24 hours in Rcho-1 TG cells.  (A) Specific 
targeted protein bands as detected by respective antibodies via Western blot. (B) Protein 
levels of P-eIF2α, eIF2α, and ratio of P-eIF2α:eIF2α at 6 hours and (C) 24 hours of nicotine 
exposure. (D) Protein levels of CHOP at 6 hours and (E) 24 hours of nicotine exposure. 
All arbitrary values were expressed as means normalized to Amido Black ± SEM. All 
experiments were performed in quadruplicates (n=4). Significant differences between 
treatment groups as determined by one-way ANOVA (1WA) indicated by ** (p<0.01) or 
*** (p<0.001). Different letters represent means that are significantly different from one 
another according to Tukey’s post-test (p<0.05). Non-significant differences (p>0.05) 
indicated by n.s. 
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To investigate several other markers of the UPR, we measured protein levels of two 
chaperone proteins: BiP/GRP78, a chaperone protein up-regulated during ER stress to 
assist with protein re-folding [49], and PDI, a key enzyme and chaperone protein involved 
in disulfide bond formation in protein folding [50-53]. Both markers were found to be 
unaltered by nicotine after 6 and 24 hours (Figure 3.4A-E). 
To assess general placental TG cell function and differentiation in response to varying 
doses of nicotine (0, 1, 10μM), we measured the steady-state mRNA levels of Pl-1, 
placental growth factor (Pgf), and heart-and-neural-crest-derivatives-expressed 1 (Hand1) 
via RT-PCR. Pl-1 is a member of the placental lactogen/pro-lactin family of hormones, 
uniquely expressed by TG cells, and carries many biological roles in pregnancy (i.e., 
mammary gland development, immune regulation, stimulation of progesterone 
biosynthesis in corpus luteum) [30, 54]. Pgf is a member of the vascular endothelial growth 
factor family and carries important roles in placental vasculogenesis and angiogenesis [55]. 
Hand1 is a transcription factor essential for TG cell differentiation and placental 
development [24]. Pl-1, Pgf, and Hand1 mRNA levels did not demonstrate any significant 
changes in response to nicotine compared to the control after 24 hours (Figure 3.5A-C). 
In addition, we also measured the effect of varying doses of nicotine (1-100μM) on protein 
levels of ATF4, GCN2, and VKORC1. There were no significant differences across the 
nicotine doses in these targets (Appendix I, Supplemental Figure 3).  
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Figure 3.4. The effect of various doses of nicotine exposure (0.1-100μM) on markers 
of the unfolded protein response after 6 and 24 hours in Rcho-1 TG cells.  (A) Specific 
targeted protein bands as detected by respective antibodies via Western blot. (B) Protein 
levels of BiP at 6 hours and (C) 24 hours of nicotine exposure. (D) Protein levels of PDI at 
6 hours and (E) 24 hours of nicotine exposure. All arbitrary values were expressed as means 
normalized to Amido Black ± SEM. All experiments were performed in quadruplicates 
(n=4). Non-significant differences (p>0.05) indicated by n.s. 
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Figure 3.5. The effect of various doses of nicotine (0, 1, 10μM) on markers of placental 
TG cell function and differentiation after 24 hours in Rcho-1 TG cells. mRNA levels 
of (A) Pl-1, (B) Pgf, and (C) Hand1. All arbitrary values were expressed as means 
normalized to the geometric mean of β-Actin and Gapdh ± SEM. All experiments were 
performed in quadruplicates (n=4). Non-significant differences (p>0.05) indicated by n.s. 
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3.3.3 Nicotine-induced PERK phosphorylation can be blocked by 
nAChR antagonist 
To further verify the direct binding of nicotine to nAChRs, Rcho-1 TG cells were pre-
treated for 1 hour with 10μM mecamylamine hydrochloride (MH; a non-competitive, total 
nAChR inhibitor), and then treated with 10μM nicotine for 6 or 24 hours. MH dose was 
chosen based on previously published findings demonstrating effective nAChR blocking 
against nicotine [56-58].  We selected PERK phosphorylation as the protein target to 
quantify the effect due to the previously observed robust changes to nicotine. Treatment 
with 10μM nicotine led to significantly increased PERK phosphorylation (P<0.05), and 
pre-treatment for 1 hour with 10μM MH completely blocked nicotine-induced increases in 
PERK phosphorylation (p<0.05; Figure 3.6A, B), verifying involvement of direct binding 
of nicotine to nAChRs in the induction of ER stress. MH pre-treatment alone did not induce 
any effects on PERK phosphorylation. 
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Figure 3.6. Pre-treatment with 10μM MH blocked nicotine-induced PERK 
phosphorylation after 6 hours in Rcho-1 TG cells. (A) Specific targeted protein bands 
as detected by respective antibodies via Western blot. (B) Protein levels of P-PERK, 
PERK, and ratio of P-PERK: PERK at 6 hours. All arbitrary values were expressed as 
means normalized to Amido Black ± SEM. All experiments were performed in 
quadruplicates (n=4). 
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3.3.4 Hypoxia dose-dependently increased the phosphorylation of 
PERK in Rcho-1 rat placental TG cells in vitro 
We previously demonstrated that maternal nicotine exposure can induce hypoxia (e.g., 
increased HIF1α, CA-IX) in the rat placenta in vivo [8, 13]. Given that hypoxia is also 
capable of augmenting ER stress [59, 60], we sought to next investigate the possible effects 
of hypoxia on placental ER stress in Rcho-1 TG cells. After 10 days of differentiation in 
NCTC-135 + 1% horse serum at 37oC in 95% room air/5% CO2 [30], Rcho-1 TG cells 
were exposed to either 20%, 8%, or 1% oxygen for 6 or 24 hours. The range of oxygen 
concentrations included: the recommended in vitro oxygen tension for growing Rcho-1 
cells (20%), the representative physiological oxygen tension for second or third trimester 
placentas (8%; considered mild hypoxia), and the oxygen tension previously shown to 
effectively induce hypoxia in trophoblast cells (1%; considered moderate hypoxia) [61]. 
Oxygen levels were regulated through the use of individual hypoxic culturing chambers. 
To prevent the effects of hypoxic re-oxygenation, cells were sealed inside appropriately 
acclimated Ziploc bags during transfer from hypoxic chamber and instantly lysed in RIPA 
or TRIzol for protein or RNA isolation, respectively. 
To verify the effective induction of hypoxia through decreased oxygen levels in Rcho-1 
TG cells, we measured HIF1α protein levels at 20%, 8%, and 1% oxygen. Rcho-1 TG cells 
exposed to 8% and 1% oxygen demonstrated significantly increased HIF1α protein levels 
after 6 hours (p<0.001) and 24 hours (p<0.05) compared to 20% oxygen (Figure 3.7A-C), 
verifying increasing hypoxia with decreasing oxygen. 
Decreasing oxygen levels also led to significant dose-dependent increases in the ratio of P-
PERK:PERK at both 6 hours (p<0.05) and 24 hours (p<0.01; Figure 3.8A-C), suggesting 
increasing PERK activation and ER stress induction with increasing hypoxia. 
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Figure 3.7. Decreasing oxygen levels induced HIF1α protein levels after 6 and 24 
hours in Rcho-1 TG cells. (A) Specific targeted protein bands as detected by respective 
antibodies via Western blot. (B) Protein levels of HIF1α after 6 hours, and (C) 24 hours. 
All arbitrary values were expressed as means normalized to Amido Black ± SEM. All 
experiments were performed in quadruplicates (n=4). Significant differences between 
treatment groups as determined by one-way ANOVA (1WA) indicated by * (p<0.05) or 
*** (p<0.001). Different letters represent means that are significantly different from one 
another according to Tukey’s post-test (p<0.05).  
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Figure 3.8. Decreasing oxygen levels induced dose-dependent increases in 
phosphorylation of PERK after 6 and 24 hours in Rcho-1 TG cells. (A) Specific 
targeted protein bands as detected by respective antibodies via Western blot. (B) Protein 
levels of P-PERK, PERK, and ratio of P-PERK:PERK after 6 hours, and (C) 24 hours. All 
arbitrary values were expressed as means normalized to Amido Black ± SEM. All 
experiments were performed in quadruplicates (n=4). Significant differences between 
treatment groups as determined by one-way ANOVA (1WA) indicated by * (p<0.05) or 
** (p<0.01). Different letters represent means that are significantly different from one 
another according to Tukey’s post-test (p<0.05). Non-significant differences (p>0.05) 
indicated by n.s. 
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Downstream of PERK, 1% oxygen led to a significant increase in protein levels of P-eIF2α 
compared to 8% oxygen, though neither were significantly different from 20% oxygen 
(Figure 3.9A, C). There were no significant changes in the ratio of P-eIF2α:eIF2α with 
changing oxygen levels at 6 or 24 hours (Figure 3.9A-C). Protein levels of CHOP appeared 
to be trending towards a dose-dependent increase with decreasing oxygen levels at 6 hours, 
though it did not reach statistical significance. Varying oxygen levels also led to significant 
changes in CHOP protein levels at 24 hours (p<0.05) (Figure 3.9A, E). Interestingly, 
CHOP protein levels were not significantly different at 8% nor 1% O2 compared to 20% 
oxygen. However, CHOP protein levels were significantly decreased at 1% oxygen 
compared to 8% oxygen. This was surprising, as CHOP expression was previously 
demonstrated to be selectively up-regulated in the presence of ER stress and UPR 
activation in rat placentas in vivo and mouse embryonic fibroblasts in vitro [13, 62]. 
Therefore, we wondered if this decrease in CHOP was perhaps attributable to some non-
UPR-directed regulation of protein expression (i.e., Akt1-mTOR pathway) in response to 
moderate hypoxia [63]. 
To inquire into the possible involvement of non-UPR-directed translational regulation of 
CHOP at 24 hours, we measured the protein levels of Akt1 and the phosphorylation of 
mTOR due to their canonical role in protein translation [63]. We found significant changes 
in protein levels of Akt1 (p<0.05) and the phosphorylation of mTOR (p<0.05) with varying 
oxygen levels (Figure 3.10A-C). Trends mirrored the changes on CHOP, where neither 8% 
nor 1% oxygen caused any changes in protein levels compared to 20% oxygen, but 1% 
oxygen led to significantly decreased protein levels compared to 8% oxygen. 
To investigate several other markers of the UPR, we measured protein levels of BiP and 
PDI. BiP protein levels appeared to have a trending increase with decreasing oxygen levels, 
however, levels did not reach statistical significance (Figure 3.11A-C). PDI protein levels 
demonstrate significant dose-dependent increases with decreasing oxygen levels at 6 hours 
(Figure 3.11D-F), collectively suggesting mild acute increases in chaperone proteins in 
response to hypoxia. 
97 
 
 
  
98 
 
Figure 3.9. The effects of decreasing oxygen levels on UPR targets downstream of 
PERK after 6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as 
detected by respective antibodies via Western blot. (B) Protein levels of P-eIF2α, eIF2α, 
and ratio of P-eIF2α:eIF2α after 6 hours, and (C) 24 hours. (D) Protein levels of CHOP 
after 6 hours and (E) 24 hours. All arbitrary values were expressed as means normalized to 
Amido Black ± SEM. All experiments were performed in quadruplicates (n=4). Significant 
differences between treatment groups as determined by one-way ANOVA (1WA) 
indicated by * (p<0.05). Different letters represent means that are significantly different 
from one another according to Tukey’s post-test (p<0.05). Non-significant differences 
(p>0.05) indicated by n.s. 
  
99 
 
 
Figure 3.10. The effects of decreasing oxygen levels on the Akt-mTOR pathway after 
6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as detected by 
respective antibodies via Western blot. Protein levels of (B) Akt1 and (C) P-mTOR, mTOR 
and ratio of P-mTOR:mTOR after 24 hours. All arbitrary values were expressed as means 
normalized to Amido Black ± SEM. All experiments were performed in quadruplicates 
(n=4). Significant differences between treatment groups as determined by one-way 
ANOVA (1WA) indicated by * (p<0.05). Different letters represent means that are 
significantly different from one another according to Tukey’s post-test (p<0.05). Non-
significant differences (p>0.05) indicated by n.s. 
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Figure 3.11. The effects of decreasing oxygen levels on BiP and PDI protein levels 
after 6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as detected 
by respective antibodies via Western blot. (B) Protein levels of BiP after 6 hours, and (C) 
24 hours. (D) Specific targeted protein bands as detected by respective antibodies via 
Western blot. (E) Protein levels of PDI after 6 hours, and (C) 24 hours. All arbitrary values 
were expressed as means normalized to Amido Black ± SEM. All experiments were 
performed in quadruplicates (n=4). Significant differences between treatment groups as 
determined by one-way ANOVA (1WA) indicated by * (p<0.05). Different letters 
represent means that are significantly different from one another according to Tukey’s 
post-test (p<0.05). Non-significant differences (p>0.05) indicated by n.s. 
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To assess general placental TG cell function and differentiation in response to hypoxia, we 
measured the steady-state mRNA levels of Pl-1, Pgf, and Hand1 via RT-PCR. Pl-1 mRNA 
levels did not demonstrate any significant changes in response to decreasing oxygen 
(Figure 3.12A). However, Pgf and Hand1 mRNA levels decreased significantly at 8% and 
1% oxygen compared to 20% oxygen (p<0.001; Figure 3.12B, C). 
 
 
Figure 3.12. The effects of decreasing oxygen levels on markers of placental TG cell 
function and differentiation after 24 hours in Rcho-1 TG cells. mRNA levels of (A) Pl-
1 after 24 hours, (B) Pgf after 24 hours, and (C) Hand1 after 24 hours. All arbitrary values 
were expressed as means normalized to the geometric mean of β-Actin and Gapdh ± SEM. 
All experiments were performed in quadruplicates (n=4). Significant differences between 
treatment groups as determined by one-way ANOVA (1WA) indicated by *** (p<0.001). 
Different letters represent means that are significantly different from one another according 
to Tukey’s post-test (p<0.001). Non-significant differences (p>0.05) indicated by n.s. 
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3.3.5 The combinative effects of nicotine and hypoxia on ER stress 
and PERK phosphorylation 
Since we observed that nicotine and hypoxia both independently have the ability to induce 
ER stress and UPR activation in Rcho-1 TG cells, we were next interested in investigating 
whether nicotine and hypoxia might have an interaction effect. We selected PERK and 
eIF2α phosphorylation as protein targets to quantify the effect, as they previously 
responded robustly to either nicotine or hypoxia. Rcho-1 TG cells were then treated with 
nicotine (0, 1, or 10μM) at either 20%, 8%, or 1% oxygen for 6 or 24 hours. 
To first verify the effectiveness of our hypoxic conditions and to ensure that nicotine 
exposure has no effect on the induction of hypoxia in vitro, we measured protein levels of 
HIF1α. Rcho-1 TG cells exposed to decreased oxygen levels demonstrated significantly 
increased HIF1α protein levels after both 6 hours (p<0.001) and 24 hours (p<0.05) 
compared to 20% oxygen, verifying the induction of hypoxia. Nicotine caused no 
significant treatment effect on the protein levels of HIF1α (Figure 3.13A-C). 
Decreasing oxygen levels also led to a significant treatment effect on the phosphorylation 
of PERK at both 6 hours (p<0.05) and 24 hours (p<0.001), with 1% oxygen causing the 
greatest increase in PERK phosphorylation (Figure 3.14A-C). Trends within the 20% O2 
group paralleled previous findings (Figure 3.2), with nicotine dose-dependently increasing 
PERK phosphorylation at 6 hours, though the two-way ANOVA analysis did not identify 
any statistically significant changes. However, the trending nicotine effect no longer held 
at 8% or 1% oxygen. There were no significant interaction effects between nicotine and 
hypoxia on the phosphorylation of PERK according to two-way ANOVA analysis. 
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Figure 3.13. The combinative effects of nicotine and hypoxia on HIF1α protein levels 
after 6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as detected 
by respective antibodies via Western blot. (B) Protein levels of P-PERK, PERK, and ratio 
of P-PERK:PERK after 6 hours, and (C) 24 hours. All arbitrary values were expressed as 
means normalized to Amido Black ± SEM. All experiments were performed in 
quadruplicates (n=4). Significant differences between treatment effect as determined by 
two-way ANOVA (2WA) indicated by * (p<0.05) or *** (p<0.001). Treatment effect due 
to oxygen on protein levels indicated by 2WA - O2. 
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Figure 3.14. The combinative effect of nicotine and hypoxia on phosphorylation of 
PERK after 6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as 
detected by respective antibodies via Western blot. (B) Protein levels of P-PERK, PERK, 
and ratio of P-PERK:PERK after 6 hours, and (C) 24 hours. All arbitrary values were 
expressed as means normalized to Amido Black ± SEM. All experiments were performed 
in quadruplicates (n=4). Significant differences between treatment effect as determined by 
two-way ANOVA (2WA) indicated by * (p<0.05) or *** (p<0.001). Treatment effect due 
to oxygen on protein levels indicated by 2WA - O2. Non-significant differences (p>0.05) 
indicated by n.s. 
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Downstream of PERK, varying oxygen levels significantly affected the phosphorylation of 
eIF2α at 24 hours (p<0.05; Figure 3.15A-C). Nicotine did not induce any significant 
treatment effect according to two-way ANOVA analysis. Similar to PERK, trends within 
the 20% oxygen group paralleled previous findings (Figure 3.3) with nicotine dose-
dependently increasing the phosphorylation of eIF2α at 6 hours, though the two-way 
ANOVA analysis did not identify significant changes. The nicotine effects also no longer 
held at 8% or 1% oxygen. There were no significant interaction effects between nicotine 
and hypoxia on the phosphorylation of eIF2α according to two-way ANOVA analysis. 
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Figure 3.15. The combinative effects of nicotine and hypoxia on phosphorylation of 
eIF2α after 6 and 24 hours in Rcho-1 TG cells. (A) Specific targeted protein bands as 
detected by respective antibodies via Western blot. (B) Protein levels of P-eIF2α, eIF2α, 
and ratio of P-eIF2α:eIF2α after 6 hours, and (C) 24 hours. All arbitrary values were 
expressed as means normalized to Amido Black ± SEM. All experiments were performed 
in quadruplicates (n=4). Significant differences between treatment effect as determined by 
two-way ANOVA (2WA) indicated by * (p<0.05). Treatment effect due to oxygen on 
protein levels indicated by 2WA - O2. Non-significant differences (p>0.05) indicated by 
n.s. 
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3.3.6 The effects of Tauroursodeoxycholic acid (TUDCA) on 
nicotine-induced ER stress, PERK activation, and 
downstream placental TG function 
Lastly, we were interested in assessing TUDCA as a potential novel therapeutic approach 
to protect against nicotine-induced ER stress in the placenta. After 10 days of 
differentiation in NCTC-135 + 1% horse serum in 95% room air/5% CO2 [30], Rcho-1 TG 
cells were pre-treated for 1 hour with 100μM TUDCA, and then treated with 10μM nicotine 
for 6 or 24 hours. TUDCA dose was selected based on previously published findings that 
effectively reduced ER stress in vitro [64, 65]. We selected PERK phosphorylation as the 
protein target to quantify the effect due to the previously observed robust changes to 
nicotine. Treatment with 10μM nicotine led to significantly increased PERK 
phosphorylation (P<0.05) in Rcho-1 TG cells, and pre-treatment with 100μM TUDCA 
completely inhibited nicotine-induced increases in PERK phosphorylation (P<0.05; Figure 
3.16A, B). TUDCA pre-treatment alone did not induce any effects on PERK 
phosphorylation.  
To assess general placental TG cell function and differentiation in response to TUDCA, 
we measured the steady-state mRNA levels of Pl-1, Pgf, and Hand1 via RT-PCR. Pl-1 and 
Pgf mRNA levels did not demonstrate any changes in response to TUDCA pre-treatment 
nor nicotine treatment (Figure 3.17A, B). However, pre-treatment with TUDCA led to 
significantly decreased Hand1 mRNA levels at 24 hours compared to both control and 
nicotine treatment groups (p<0.01 and p<0.05, respectively; Figure 3.17C). 
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Figure 3.16. Pre-treatment with 100μM TUDCA prevents nicotine-induced PERK 
phosphorylation after 6 hours in Rcho-1 TG cells. (A) Specific targeted protein bands 
as detected by respective antibodies via Western blot. (B) Protein levels of P-PERK, 
PERK, and ratio of P-PERK: PERK at 6 hours. All arbitrary values were expressed as 
means normalized to Amido Black ± SEM. All experiments were performed in 
quadruplicates (n=4). Significant differences between treatment groups determined by one-
way ANOVA (1WA) followed by Tukey’s post-test were indicated by * (p<0.05; 
significant difference from control), ≠ (p<0.05; significant difference from nicotine), or ≠≠ 
(p<0.01; significant difference from nicotine). 
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Figure 3.17. The effects of TUDCA (100μM) and/or nicotine (10μM) on various 
markers of placental TG cell function and differentiation after 24 hours in Rcho-1 
TG cells. mRNA levels of (A) Pl-1, (B) Pgf, and (C) Hand1 after 24 hours. All arbitrary 
values were expressed as means normalized to the geometric mean of β-Actin and Gapdh 
± SEM. All experiments were performed in quadruplicates (n=4). Significant differences 
between treatment groups determined by one-way ANOVA (1WA) followed by Tukey’s 
post-test indicated by ** (p<0.01; significant difference from control) and ≠ (p<0.05; 
significant difference from nicotine).  
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3.4 Discussion 
Maternal nicotine exposure was recently demonstrated to augment ER stress in the rat 
placenta in vivo, however, it had yet to be discriminated the degree to which the direct 
and/or indirect cellular effects of nicotine were responsible.  In this study, we firstly 
demonstrated that nicotine can directly augment ER stress and UPR activation in Rcho-1 
placental TG cells, as seen through dose-dependent increases in PERK and eIF2α 
phosphorylation. This was further verified by successful blocking of nicotine-induced 
PERK phosphorylation using MH, a nAChR antagonist. Secondly, we revealed that 
hypoxia, which is a potential indirect effect of nicotine exposure on the placenta in vivo [8, 
13], can also dose-dependently induce ER stress in Rcho-1 TG cells in vitro. However, no 
statistically significant interaction effect was seen in the combined experiments using both 
nicotine and hypoxia. Lastly, we utilized TUDCA in a novel manner to prevent nicotine-
induced PERK phosphorylation in placental TG cells. Though choriocarcinoma cell lines 
are admittedly limited in some ways due to their transformed phenotype, they may still 
serve as good models to dissect the cellular mechanisms and relationships underlying 
complex in vivo situations. Rcho-1 cells are very well characterized and determined to 
exhibit many similarities to true placental TG cells in cell cycle regulation, differentiation, 
gene transcription profile, transport processes, hormone production, and others (please 
refer to [66] for full reference list on conducted studies). Furthermore, Rcho-1 cells are 
remarkable in their versatile ability to fully differentiate into TG cells, allowing our study 
of the nicotine-induced ER stress response in that particular trophoblast cell type. 
Placental TG cells exposed to nicotine in vivo likely experienced the effects of both nAChR 
activation and hypoxia [13], though the degree to which they individually and 
synergistically induced ER stress remained largely enigmatic. Repo et al. (2014) had 
preliminarily assessed the direct effects of nicotine on ER stress in BeWo cells; however, 
the single super-physiological dose of nicotine used (15μM) and minimal markers of ER 
stress measured (only BiP and IRE1α) urged for a more comprehensive investigation [67]. 
Our findings in Rcho-1 TG cells now elucidate two possible mechanisms by which nicotine 
may induce ER stress in placental TG cells: (1) directly through nAChR activation and (2) 
indirectly through hypoxia. These in vitro results also identify the underlying mechanisms 
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of nicotine-induced ER stress augmentation previously seen in the rat placenta in vivo [13]. 
However, unlike previous in vivo results [13], downstream UPR activation of targets such 
as ATF4, CHOP, BiP, PDI, VKORC1, and GCN2 were far less prominent in response to 
nicotine and/or hypoxia, despite the strength of PERK and/or eIF2α activation. Longer and 
more chronic exposures to nicotine and/or hypoxia may be required to alter these 
downstream targets (e.g., previous studies performed month-long daily nicotine injections 
in vivo [13], or 3 days of chronic hypoxia in vitro [18] to demonstrate effects). This also 
provides a possible explanation for the lack of change seen in markers of TG cell function 
and differentiation (e.g., Pl-1, Pgf, and Hand1), despite previously reported changes upon 
exposure to nicotine or ER stress in rodent placentas in vivo [8, 20]. However, our study 
was mainly purposed to investigate the activation the UPR via acute nicotine exposure, 
which we were indeed able to examine through PERK phosphorylation. 
Furthermore, our findings indicating that hypoxia increased ER stress and PERK 
phosphorylation were consistent with Yung et al. (2012), who demonstrated increased UPR 
activation in JEG-3 and BeWo cells after 3 days of culture at 1% oxygen [18]. In our 
experiments, however, CHOP protein levels unexpectedly decreased from 8% to 1% 
oxygen after 24 hours despite dose-dependent increases in PERK activation. Conversely, 
other studies have shown that protein levels of CHOP increased in response to 1% oxygen 
after 24 hours in human melanoma cells in vitro [68]; though, changes were not seen rat 
myocardial tissue exposed to hypobaric hypoxia in vivo [69]. Also, Chop mRNA levels 
strongly increased in response to severe hypoxia (0% oxygen) in HeLa cells in vitro; yet, 
specific translation of Chop transcripts demonstrated little to no change as determined 
through ribosomal-transcript interaction [59]. This inconsistency seen across various 
studies suggests that CHOP expression may be differentially regulated dependent on 
cell/tissue type, severity of hypoxia, and experimental model. We further investigated the 
Akt-mTOR protein translation pathway and saw parallel changes across CHOP, Akt1, and 
P-mTOR:mTOR protein levels, suggesting that the changes seen in CHOP protein levels 
may be due to altered protein translation regulation via the Akt-mTOR pathway in response 
to hypoxia. Hypoxia is known to inhibit mTOR complex 1-regulated protein translation 
initiation [63], which may specifically suppress the translation of various transcripts [59], 
perhaps including Chop mRNA. Nonetheless, these findings are only correlative and no 
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studies have been conducted to date investigating the direct effect of Akt-mTOR-regulated 
protein translation on CHOP protein levels, thus more experiments are needed to verify a 
causal relationship.  
Strikingly, hypoxia strongly suppressed the mRNA levels of Hand1 and Pgf. Murine hearts 
exposed to hypoxia in vivo led to increased Hand1 mRNA levels, which contrasted with 
our findings [70]; however, there are no published studies to date reporting the effects of 
hypoxia or ER stress on Hand1 expression in the placenta. More consistently, primary 
human syncytiotrophoblasts exposed to 1% oxygen demonstrated strongly suppressed Pgf 
mRNA levels, though the underlying regulatory mechanisms remained unclear [71]. 
Maternal exposure to tunicamycin, a drug that induces ER stress through inhibition of 
protein N-glycosidic linkage formation, also impaired placental Pgf expression alongside 
compromised placental development [20]. Considering that ER stress and UPR activation 
were seen in association with impaired Pgf expression in Rcho-1 TG cells exposed to acute 
hypoxia in our study, it is possible that hypoxia-induced ER stress may underlie the 
impairment of Pgf expression. This is an important preliminary finding warranting further 
investigation in vivo, as the reestablishment of ER function may be linked to the desirable 
restoration of Pgf expression under hypoxia.  
Despite the individual effects of nicotine and hypoxia on ER stress, we did not detect any 
statistically significant interaction effects between the two insults. However, we no longer 
saw dose-dependent effects of nicotine on PERK and eIF2α phosphorylation at decreased 
oxygen levels of 8% or 1%. One possible explanation is that the severity of hypoxia in 
comparison to the milder nAChR activation masked any noticeable nicotine-induced 
effects on ER stress, though this is merely speculative. A more likely explanation is that 
moderate hypoxia down-regulated nAChR expression, which has been seen in other tissue 
types [72, 73], thus leading to a decreased effect of nicotine on ER stress under hypoxia. 
This also suggests that the nicotine-induced ER stress augmentation previously seen in the 
whole placenta in vivo may be predominantly caused by nicotine-induced hypoxia and less 
so by nAChR activation, since placental tissues exposed to nicotine were found to be 
hypoxic [13]. Future studies are directed to investigate the effects of hypoxia on the 
expression of various nAChR subtypes in the placenta to clarify these results.  
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Findings from our study are the first to reveal that TUDCA can prevent nicotine-induced 
PERK activation in placental TG cells. TUDCA is suggested to ameliorate ER stress either 
through direct assistance with protein folding or increasing the expression of molecular 
chaperones [28]. Exogenous supplementation has provided beneficial effects in treating 
neurodegenerative and metabolic diseases, and other protein folding disorders (e.g., 
obesity, type 2 diabetes, Alzheimer’s disease) [29, 74]. Both TUDCA and UDCA, the non-
taurine-conjugated counterpart of TUDCA, are approved by the FDA for treating primary 
biliary cirrhosis; however, TUDCA has been demonstrated to possess more favourable 
metabolic properties for longer-term use [75, 76]. Recent developmental studies further 
demonstrated that postnatal TUDCA injections can reverse prenatal ethanol-induced ER 
stress damage in liver and skeletal muscle of rat offspring [77, 78]. Alongside the 
favourable effects against ER stress, TUDCA may also inhibit ROS production and protect 
against mitochondrial-mediated and caspase-mediated apoptosis [79-81], perhaps 
collectively enriching global cellular health. These properties of TUDCA may be 
especially desirable during pregnancy, as the placenta is particularly susceptible to 
oxidative and ER stress augmentation due to high protein folding and secretory activity 
[19]. However, mild decreases seen in Hand1 mRNA levels following TUDCA treatment 
in vitro suggest that TUDCA may potentially influence placental trophoblast cell 
differentiation; though more extensive experimentation would be required before 
conclusions may be made. Overall, given the effectiveness of TUDCA in relieving 
nicotine-induced ER stress in the current study, it will be of great interest to examine the 
potential benefits of TUDCA on hypoxia-induced ER stress in Rcho-1 TG cells in vitro, 
nicotine-induced ER stress in the placenta in vivo, and ultimately, as a novel therapeutic 
agent to remedy the consequences of maternal nicotine exposure in the clinical setting.  
In conclusion, our current in vitro study provides strong mechanistic insight on the direct 
and indirect effects of nicotine exposure on placental ER stress and trophoblast cell 
function and differentiation (summarized in Figure 3.18). Our findings further demonstrate 
that TUDCA supplementation may indeed be a promising therapeutic option to consider 
for treating the negative outcomes of maternal nicotine exposure, though more studies are 
needed in order to assess its safety in pregnancy. With the high rates of maternal nicotine 
exposure that continue to occur worldwide, research in intervention development is 
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urgently required for those afflicted. Nonetheless, the compliant usage or abstinence from 
these nicotine-containing products remain most heavily influenced by “approval from 
healthcare professional[s]” [82], thus we must continue to raise the clinical voice in this 
transgenerational battle against nicotine use during pregnancy. 
 
 
 
Figure 3.18. Direct nAChR activation and indirect hypoxia both induce ER stress and 
UPR activation in placental TG cells. The effects of nAChR activation were less 
prominent at increased hypoxia possibly due to either a masking effect or nAChR down-
regulation. TUDCA also inhibited nicotine-induced PERK activation, but its potential 
effects on hypoxia-induced ER stress have yet to be determined. Chronic ER stress and 
UPR activation may lead to impaired placental TG cell function and differentiation, which 
may in turn compromise development and function in the whole placenta. 
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Excerpts of this chapter have been submitted for publication and currently in revision: 
Wong MK, Barra NG, Alfaidy NN, Hardy DB, and Holloway AC. Adverse effects of 
perinatal nicotine exposure on reproductive outcomes. Reproduction, in revision.   
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4.1 Summary 
It is now becoming better understood that even maternal nicotine exposure alone can lead 
to deleterious outcomes in pregnancy and long-term health. Nicotine is known to directly 
pass through the placental barrier, accumulate in fetal serum, and exert its effects on 
developing tissues [1-3]. Alternatively, we are now aware that nicotine may also impair 
development of the placenta [4], which indirectly compromises the well-being of the 
growing fetus. However, many of the cellular mechanisms underlying the effects of 
nicotine on the placenta had yet to be discovered. To reiterate the rationale for this thesis, 
recent findings demonstrated that nicotine exposure leads to increased hypoxia in the 
placenta [4-6] and placental insufficiency [4]. Furthermore, hypoxia and placental 
insufficiency were both strongly associated with ER stress [7-11]. Based on this, we were 
interested in determining whether nicotine exposure leads to ER stress in the placenta.  
In the present studies, nicotine exposure led to augmented ER stress and UPR activation in 
the rat placenta both in vivo and in vitro, supporting the hypothesis. This was associated 
with impaired disulfide bond formation, hypoxia, and amino acid starvation at e15 in vivo, 
though it remained unclear how nicotine exposure induced ER stress at the cellular level 
[12]. Upon further investigation using the well-established Rcho-1 TG cells, we concluded 
that ER stress may be augmented in the placenta both directly through nAChR activation 
and indirectly through hypoxia in vitro. Additionally, since hypoxia masked the effects of 
nAChR activation on ER stress in the combined hypoxia and nicotine experiments in vitro, 
we deduced that the placental ER stress occurring in vivo may be predominantly attributed 
to nicotine-induced hypoxia. After identifying the involvement of ER stress in nicotine-
induced placental injury, we were interested in next investigating potential therapeutic 
interventions. By pre-treating Rcho-1 TG cells with TUDCA, we were the first to 
successfully prevent nicotine-induced ER stress and UPR activation in the placenta in vitro, 
encouraging future studies to assess its full potential for alleviating the detrimental 
outcomes of maternal nicotine exposure in pregnancy. In this final chapter, we will identify 
some limitations of our work and conclude by discussing the implications from our studies 
for future research directions in this field.    
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4.2 Limitations and Improvements  
In order to improve the quality of future studies, we will address some of the major 
limitations of our current work. Firstly, the molecular techniques used to quantify ER stress 
and UPR activation in both studies were limited to quantification of protein and mRNA 
levels via Western blot and Real-time PCR. Though these methods are theoretically sound, 
since quantifying expression changes in the UPR pathways indicate the presence of ER 
stress [13, 14], it is unable to directly measure the accumulation of misfolded proteins 
which truly defines ER stress, nor does it allow for real-time, live cell monitoring [15, 16]. 
One recently discovered technique that may overcome both these limitations involves the 
use of a fluorescently-tagged chaperone protein, such as green fluorescence protein-tagged 
BiP (BiP-GFP), paired with Fluorescence Recovery After Photobleaching (FRAP) [17]. 
The molecular chaperone BiP inherently detects and binds misfolded proteins within the 
ER lumen [18], which slows down its diffusional mobility. FRAP then allows for the 
quantification of BiP-GFP diffusional mobility, which provides real-time information on 
changes in misfolded protein burden and ER stress in live cells [17].  
Secondly, our analysis of ER stress and UPR activation in vivo was limited to whole rat 
placentas. Although it is undoubtedly important to determine the effects on the organ as a 
whole, the study could be improved in two ways. Given the heterogeneous anatomy of the 
placenta, we should further analyze the ER stress response within specific regions [19]. 
Nicotine was previously demonstrated to induce region-specific effects within the rat 
placenta (e.g., nicotine exposure only impaired growth in decidua and junctional zone, but 
not in labyrinth zone [4]). Experimental augmentation of ER stress in murine placenta also 
led to region-specific inductions of the UPR (e.g., ER stress mouse model led to PERK 
activation in junctional zone, but not labyrinth zone [9]), thus it is possible that nicotine-
induced ER stress may be differentially augmented in specific placental regions. 
Furthermore, to extend the relevance of our findings back to the clinical setting, it would 
be very informative to pair our examination of the ER stress response in the rat placenta 
with human placentas exposed to NRTs/e-cigarettes during pregnancy.  
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Thirdly, our in vivo study was limited to only one time-point (e15) and nicotine dose 
(1mg/kg). This time-point was specifically chosen as nicotine exposure previously led to 
structural and morphological aberrations in the rat placenta at e15, prior to any observable 
fetal growth deficits [12]. However, it was known that rat offspring exposed to nicotine 
exposure in utero would be eventually have low birth weights at term compared to controls 
[20]. Given that ER stress and placental insufficiency were observed to precede IUGR in 
humans [10, 11, 21, 22], determining the presence of ER stress at the e15 time-point would 
reveal a potential mechanism through which nicotine may cause adverse placental and fetal 
outcomes in pregnant mothers who are smoking or using NRTs. However, the study could 
be improved by analyzing several other time-points to observe the progression of ER stress 
in response to chronic nicotine. Furthermore, we found significantly increased CHOP 
expression at e15 with no changes in markers of apoptosis (e.g., ratio of BAX to BCL2, 
Bim, Puma, caspase pathway) [12]. Though we have speculations that CHOP activation 
may have been at an early stage and apoptosis might be amplified later on in pregnancy, 
measurements at a later time-point would have provided concrete evidence to confirm this. 
Furthermore, using more than one nicotine dose would have allowed us to determine the 
dose-dependent relationship between nicotine and ER stress in the placenta in vivo. We 
attempted to overcome this by treating Rcho-1 TG cells with a large range of nicotine doses 
(0.1-100μM) in our in vitro experiments that encompass the average serum levels found in 
humans (25nM-25μM) [23-28]; of which we were indeed able to observe dose-dependent 
increases in PERK and eIF2α phosphorylation with increasing nicotine dose. Although 
these findings do not fully extrapolate what might occur in the whole placenta in vivo, these 
in vitro experiments still provide strong support [19].  
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4.3 Implications and Future Directions 
Regardless of our findings, there are still many unanswered questions surrounding the 
complex issue of maternal nicotine exposure. In the following section, we will discuss our 
results in light of other recent breakthroughs to highlight future directions for the field.  
4.3.1 From adaptation to apoptosis: the delicate balance of PERK 
pathway activation 
It was apparent from both our in vivo and in vitro results that the PERK pathway of the 
UPR played a crucial role in responding to nicotine exposure in the placenta. Acute PERK 
activation is a necessary and adaptive response to relieve ER stress [13, 15], however, 
chronic activation is known to conversely amplify apoptosis [4, 12, 29]. As mentioned, this 
was believed to be regulated downstream of PERK by CHOP, which triggers many ER 
stress-related apoptotic pathways [15, 30]. Indeed, acute nicotine exposure in vitro did not 
affect CHOP expression in Rcho-1 TG cells, but chronic nicotine exposure in vivo elevated 
CHOP expression in rat placentas. Though we did not yet see activation of apoptosis at e15 
in association with increased CHOP, we speculated that continued nicotine exposure may 
perhaps lead to apoptosis at a later time-point [12]. The precise timing and regulation of 
this molecular switch from adaptation to apoptosis still remains unclear, however, recent 
publications reveal a growing interest in ER stress research towards the development of 
small molecule PERK pathway modulators. As future studies are directed to further 
examine the influence of the PERK pathway in nicotine-induced ER stress, we will 
highlight two recently developed compounds, GSK2656157 and ISRIB.  
GSK2656157 is a potent, highly-selective, ATP-competitive inhibitor of PERK enzyme 
activity [31, 32]. Treatments with GSK2656157 (or GSK2606414, a slightly older and less 
specific PERK inhibitor) prevented PERK phosphorylation both in vitro and in vivo, and 
inhibited subsequent downstream up-regulation of p-eIF2α, ATF4, and CHOP [31]. We 
conducted several preliminary in vitro experiments using GSK2656157 and indeed found 
effective blocking of nicotine-induced PERK activation in Rcho-1 TG cells (Appendix I, 
Supplemental Figure 4A, B). However, GSK2656157 was also demonstrated to possess 
anti-tumour properties by reducing the vascular density, perfusion, and growth of 
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xenografted tumours in mice [31-33]. PERK is involved in up-regulating pro-angiogenic 
transcripts [31]; microarray analyses revealed several pro-angiogenic transcripts that were 
preferentially translated in a PERK-dependent manner, such as VEGF and type I collagen 
inducible protein and matrix metallopeptidase 13 [34]. Although the alleviation of tumour 
growth is beneficial for combating cancer, PERK-mediated angiogenesis and perfusion is 
essential to placental development [35]. Dysregulation may lead to detrimental conditions 
such as pre-eclampsia or IUGR [36]. Though there were no adverse effects from our initial 
GSK2656157 experiments on Pl-1, Pgf, or Hand1 expression in Rcho-1 TG cells 
(Appendix I, Supplemental Figure 4C), the anti-angiogenic features of PERK-specific 
inhibition may render GSK2656157 inappropriate to treat nicotine-induced ER stress in the 
placenta during pregnancy. However, in vivo studies would be required to verify this.  
Recently, GSK2656157 was also criticized for not consistently blocking the activation of 
the associated downstream pathways [37]. In fact, PERK inhibition via GSK2656157 
treatment in human tumour cells in vitro paradoxically increased eIF2α phosphorylation, 
perhaps as a compensatory mechanism for losing the adaptive features of acute PERK 
activation [37]. Thus, though PERK activation was blocked, its downstream targets may 
still be activating. This may be due to involvement of the integrated stress response (as 
reviewed in Chapter 1). Several other kinases (PKR, HRI, and GCN2), in addition to 
PERK, converge to phosphorylate eIF2α under varying stress stimuli, hence PERK-
specific inhibition alone may not be sufficient to prevent prolonged activation of the 
downstream targets (i.e., eIF2α, ATF4, CHOP). A novel compound known as ISRIB was 
recently discovered to render cells resistant to the effects of eIF2α phosphorylation both in 
vivo and in vitro, leading to the antagonism of the integrated stress response altogether 
[38]. This restored global protein translation, inhibited ATF4/CHOP induction, and 
facilitated stress granule dissolution to free mRNA transcripts for translation [38, 39]. 
ISRIB was demonstrated to act as a potent enzyme activator of eIF2B by promoting eIF2B 
dimerization and GEF activity [40], reinstating ternary complex formation for protein 
translation even under states of stress-induced eIF2α phosphorylation. However, whether 
ISRIB releases the non-productively sequestered eIF2B from phosphorylated eIF2α or 
simply enhances the activity of residual unbound eIF2B has yet to be distinguished. 
However, its use may not be appropriate if the ER stress is still being actively augmented, 
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as co-treatment of ISRIB with tunicamycin synergistically decreased cell viability [38]. All 
in all, ISRIB may serve as an attractive therapeutic option to alleviate the negative 
outcomes of chronic PERK activation following nicotine exposure. Future studies 
determining the timing and frequency of use will be crucial to advancement of its 
applications in pregnancy.  
4.3.2 Alteration of gene expression by ER stress and the UPR  
In addition to ER stress-induced apoptosis, there are also target genes indirectly related to 
the UPR pathways that are undesirably altered by ER stress and UPR activation. One 
example mentioned in the third chapter was Pgf, a growth factor essential for placental 
angiogenesis [41]. Maternal tunicamycin treatments led to severe ER stress induction in 
association with decreased placental Pgf mRNA levels, and compromised placental 
development [11]. Our in vitro experiments exposing Rcho-1 TG cells to hypoxia also led 
to ER stress in association with impaired Pgf mRNA levels (see Figure 3.12). Though the 
exact regulatory factors responsible for these changes in expression have not yet been 
identified, augmented ER stress and UPR activation appears to be a common cellular state 
across both these models. Other examples of target genes altered in parallel manners by 
both tunicamycin and nicotine include Vegf (increased expression) and Glut1 (decreased 
expression), without any reported activation of apoptosis [4, 11, 42, 43]. Using chromatin 
immunoprecipitation (ChIP), future studies may determine the binding of specific UPR 
transcription factor proteins (i.e., ATF6, XBP1, ATF4, CHOP) to promoter/DNA binding 
sites of these target genes of interest (i.e., Pgf, Vegf, Glut1) to elucidate the transcriptional 
mechanisms that may be involved during ER stress. Though this was suggested to occur 
for stress-adaptive purposes in order to escape apoptosis [12], the changes in expression 
are often unideal long-term due to their functional importance. Moreover, altered 
transcriptional outcomes were suggested to potentially underlie the structural and 
morphological aberrations seen in nicotine-exposed placentas [12].  
4.3.3 Therapeutic agents to remedy ER stress-induced injury 
Therefore, there is incredible value in discovering therapeutic agents that may improve 
protein folding to safely protect against ER stress-related apoptosis and other impairments. 
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Normally in the body, a family of “molecular chaperones” known as heat shock proteins 
(HSPs) promote proper protein folding under situations of cellular stress, such as elevated 
temperatures, inflammation, and hypoxia. In the ER, several groups of calcium-dependent 
molecular chaperones reside to assist with protein folding, including HSP70 (also known 
as GRP78/BiP), HSP90 (also known as GRP94), calreticulin, and others [44]. Resembling 
molecular chaperones in their analogous ability to assist with protein folding comprises a 
class of non-selective small molecules known as “chemical chaperones”. While their exact 
mechanism of action remains elusive and varies across compounds, they are generally 
understood to either directly interact with misfolded proteins to facilitate their refolding, 
or indirectly increase the expression or activity of existing molecular chaperones [44].  
The endogenous taurine-conjugated bile acid, TUDCA, has received much attention due to 
its safety in vivo, and ability to relieve ER stress and associated downstream consequences 
in various metabolic and neurodegenerative experimental models [45-47]. More 
interestingly, postnatal TUDCA injections had recently been demonstrated to reverse the 
effects of prenatal ethanol-induced ER stress damage in rat liver and skeletal muscle [48, 
49]. However, its efficacy against nicotine-induced ER stress had yet to be assessed. Our 
study provided novel findings revealing the capacity of TUDCA to prevent nicotine-
induced ER stress and PERK activation in placental TG cells in vitro, directing future 
studies to verify its promising effectiveness in treating nicotine-induced ER stress in the 
placenta in vivo (please refer to Chapter 3 for a more comprehensive discussion regarding 
TUDCA). However, this ability to reduce ER stress through improving protein folding is 
not unique to TUDCA. Another popular chemical chaperone is 4-phenyl butyric acid 
(PBA), a short-chain fatty acid effective in preventing protein aggregation and promoting 
refolding through binding to hydrophobic surfaces of misfolded proteins [44]. PBA 
possesses similar effectiveness as TUDCA in the reduction of ER stress and apoptosis both 
in vitro and in vivo, and has also provided beneficial effects against various ER stress-
related metabolic and neurodegenerative disorders [45, 50, 51]. In addition, PBA is 
currently FDA-approved for treatment of urea-cycle disorders, and has demonstrated 
promise to treat thalassemia [52], beta-globin disorders [53], and potentially serve as a 
chemotherapy agent [54]. As previously mentioned, the placenta should theoretically 
benefit from the effects of these chemical chaperones due to its high susceptibility to ER 
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stress [9]. The current caveat inhibiting more widespread usage of these chemical 
chaperones is that very high doses are often required for sufficient efficacy against ER 
stress in vivo, carrying risk of side-effects [44]. Though TUDCA and PBA are safe and 
approved in humans for their current applications, future clinical studies must carefully 
determine a safe and effective dose for use in pregnancy to treat placental insults.  
4.3.4 Integrating ER stress, oxidative stress and inflammation 
Beyond ER stress and the UPR, nicotine also invokes other cellular disturbances in the 
placenta, such as oxidative stress and inflammation. Maternal smoking increased markers 
of oxidative stress in the human placenta [55]; however, nicotine exposure alone has yet to 
demonstrate evidence of increased placental ROS production or oxidative damage [4, 56, 
57]. Interestingly, placentas from nicotine-treated animals exhibited evidence of hypoxia, 
which is known to increase ROS production [58]. Moreover, nicotine-induced deficits in 
placental function may be partly ameliorated by co-administration with Vitamin C, an 
antioxidant, suggesting that oxidative stress underlies aspects of nicotine-induced placental 
deficiency [56]. The relationship between nicotine and inflammation during pregnancy 
remains controversial, where some studies proposed pro-inflammatory (PI) roles for 
nicotine [59, 60], and others proposed anti-inflammatory (AI) [61]. The discrepancies 
between studies were possibly due to variations in nicotine dose (e.g., PI: 2 mg/kg/day; AI: 
1 mg/kg/day) and duration of exposure (e.g., PI: Gestational day (GD) 1-21; AI: GD 14-
15 only) [59, 61]. However, these multidimensional effects of nicotine provoke inquiry 
into whether these three cellular mechanisms may be interconnected.  
Indeed, current research suggests that ER stress and the UPR may be further linked with 
oxidative stress and inflammation due to organelle proximity and pathway cross-talk [62]. 
The mitochondria and ER are tightly physically interconnected through mitochondrial-
associated membranes, allowing for close signalling interactions [63]. This likewise allows 
for perturbations in one organelle to affect the other (i.e., ER stress and calcium imbalance 
in the ER may also induce ROS production and oxidative stress in the mitochondria.) 
Extensive cross-talk also occurs between the pathways of these three mechanisms, such 
that their activation rarely occurs in isolation (e.g., ER stress-related PERK branch 
activation can potentially trigger inflammatory mediator NF-B, and UPR-induced 
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oxidative protein folding can also increase downstream ROS production to augment 
oxidative stress  [62]). Recent work has identified that nicotine exposure may also affect 
the epigenetic profile by altering microRNA expression [64]. microRNAs are small, non-
coding RNA molecules that fine-tune gene expression, usually through mRNA silencing. 
They have been demonstrated to be involved in the regulation of oxidative stress, 
inflammation, and ER stress, adding further intricacy to the relationship between these 
three mechanisms (e.g., PERK-NF-B pathway up-regulates miR-30c-2*, which is known 
to degrade Xbp1 transcripts [65, 66]; ATF4 may upregulate miR-211 which inhibits CHOP 
expression [67]). Indeed, we have preliminary data suggesting that maternal nicotine 
exposure significantly upregulates miR-211 levels in the rat placenta in vivo, however, the 
downstream effects have yet to be studied (p<0.05; Appendix I, Supplemental Figure 5). 
Considering all these findings, future research investigating the mechanistic underpinnings 
of maternal nicotine exposure must take an integrative approach to understand the 
synergistic involvements of oxidative stress, inflammation, ER stress, and the underlying 
epigenetic factors involved (Figure 4.1).  
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Figure 4.1. A proposed schematic illustrating the adverse effects of prenatal nicotine 
exposure on placental and long-term health outcomes, as mediated through the 
integrated induction of inflammation, oxidative stress, and ER stress. White arrows 
indicate the normal pathway within a specific mechanism, whereas black arrows indicate 
interconnected pathways between the mechanisms. miRNAs also regulate many aspects of 
these pathways (not indicated in figure).   
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4.3.5 Nicotine-induced sensitization to postnatal insults: Revisiting 
the developmental origins of health and disease theory 
In addition to the adverse effects on pregnancy and health outcomes in the offspring, 
maternal nicotine exposure may also sensitize the offspring to greater injury from other 
insults in later life. Postnatal high fat/high cholesterol diet at eleven weeks of age led to a 
greater elevation in serum IL-1β inflammatory response when mice were prenatally treated 
with nicotine, compared to mice not prenatally treated [60]. In other studies, rats 
postnatally exposed to chlorpyrifos, an organophosphate pesticide, demonstrated 
heightened and altered neurotoxic effects in their serotonergic and cholinergic systems 
when prenatally treated with nicotine, compared to rats not prenatally treated [68, 69].  
Therefore, prenatal nicotine exposure appears to create a subpopulation that is especially 
vulnerable to particular postnatal insults. By applying our understanding of the 
Developmental Origins of Health and Disease theory (as extensively reviewed in the first 
chapter), we may hypothesize that this sensitization occurs due to altered fetal 
programming and a mismatched postnatal environment. Expanding on this idea, since 
nicotine exposure is known to affect cellular nAChR expression and responsiveness, 
chronic prenatal exposure may alternatively “program” the nAChR profile of the offspring 
[70]. Hence, postnatal insults that involve nAChR signaling may exhibit an altered 
response; this likely underlies the unique postnatal chlorpyrifos-induced cholinergic 
system response seen in prenatal nicotine-exposed rats [69]. To further apply the 
“mismatched postnatal environment” element of the theory, we must also recall how 
nicotine-exposed rat offspring experience decreased birthweight [20], perhaps due to 
placental insufficiency [4], thus providing opportunity for subsequent rapid catch-up 
growth to occur. Beyond the increased risk of cardiovascular and metabolic disease that 
Barker discovered to follow combined IUGR and rapid postnatal catchup growth [71], an 
additional consequence that nicotine-exposed offspring may face is an augmented 
vulnerability to postnatal insults that might otherwise have been adaptable. Relating this 
back to the molecular focus of this thesis, would altered cellular pathways be responsible 
for the nicotine-induced sensitizations to postnatal injury? More specifically, is the greater 
vulnerability to postnatal insult after prenatal nicotine exposure attributed to increased 
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susceptibility to ER stress augmentation? Ongoing research from our lab is attempting to 
answer this question by investigating the ER stress response in livers and other organs of 
offspring that were prenatally treated with nicotine and later fed a postnatal high fat diet.  
4.3.6 The influence of maternal genetics in determining the degree 
of nicotine exposure 
To this point, our discussion has mostly focused on the effects of nicotine on the placenta 
or the fetus. However, the extent to which nicotine may induce any effect at all in these 
systems is largely determined by the initial maternal metabolism of nicotine [72]. As 
previously alluded to, there is substantial variability between individuals’ metabolomic 
capacity for nicotine due to genetic polymorphisms of essential metabolizing enzymes, 
such as CYP2A6 [73, 74]. These genetic polymorphisms have profound effects on 
individual variations in smoking behaviour and therapeutic responses to 
pharmacotherapies, since the degree of metabolism strongly influences the amount of 
nicotine available [75, 76]. Based on this, we must also consider the role of maternal 
genetics in affecting the placental and fetal exposures to nicotine in utero. More specific to 
our research, to what degree might maternal genetic polymorphisms in CYP2A6 influence 
placental exposure to nicotine, and successively affect ER stress induction in placental 
trophoblast cells? Studies are currently suggesting that maternal polymorphisms in 
CYP2A6 and other nicotine metabolizing enzymes may differentially impact the well-
being of offspring exposed to nicotine in utero [77-79], yet, the effects on the placenta have 
not been addressed. This further suggests that distinct maternal polymorphisms may place 
certain individuals more at risk to nicotine exposure during pregnancy, conveying an urgent 
need to identify, study, and treat these unique populations accordingly.  
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4.4 Conclusion 
Though there are still many complex facets left to be investigated, our findings have 
provided novel contributions to characterizing the nicotine-induced ER stress response in 
the placenta (summarized in Figure 4.2). Importantly, by elucidating these underlying 
molecular mechanisms, we may better understand the clinical pathologies associated with 
maternal nicotine exposure. Our in vitro experiments using TUDCA have also revealed 
some promising results, promoting exciting future avenues of research in the development 
of therapeutic interventions. Bearing in mind the considerable risks that still follow the 
maternal use of conventional NRTs, e-cigarettes, and other emerging forms of nicotine 
delivery [80], there remains an unprecedented need for continued research on the 
consequences of nicotine exposure during pregnancy.  
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Figure 4.2. Characterization of the nicotine-induced ER stress response in the rat 
placenta. Light grey boxes indicate findings from our in vitro experiments.  Black indicates 
findings from our in vivo experiments. Medium grey indicates findings from both in vivo 
and in vitro experiments. White indicates findings from either past research or proposed 
future areas of study. Pointed arrows indicate a potentially causal relationship. Flat arrows 
indicate an inhibitory relationship. Connecting lines indicate associations between 
findings.  
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Appendix I: Supplemental Figures 
 
Supplemental Figure 1. mRNA targets all normalized to individual housekeeping 
genes selected for geometric mean. Trends remain across all normalizations to individual 
housekeeping genes. All mRNA levels were expressed as means normalized to either β-
Actin, 18S, Gapdh, or the geometric mean ± SEM (n=5-6/group). Statistical analyses were 
not performed in these graphs. 
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Supplemental Figure 2. The effect of maternal nicotine exposure on Bim and Puma 
mRNA levels. mRNA levels of targets of interest were determined via RT-PCR. mRNA 
levels of (A) Bim and (B) Puma. All mRNA levels were expressed as means normalized 
to the geometric mean of three stable housekeeping genes (β-Actin, 18S, and Gapdh) ± 
SEM (n=5-6/group). 
 
 
 
Supplemental Figure 3. The effect of various doses of nicotine (1-100μM) on ATF4, 
GCN2, and VKORC1 after 24 hours in Rcho-1 TG cells.  (A) Specific targeted protein 
bands as detected by respective antibodies via Western blot. Protein levels of (B) ATF4, 
(C) GCN2, and (C) VKORC1. All arbitrary values were expressed as means normalized to 
β-Actin ± SEM. All experiments were performed in triplicates (n=3). There were no 
significant differences across treatment groups.  
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Supplemental Figure 4. Preliminary experiments assessing the effect of GSK2656157 
on nicotine-induced PERK activation and downstream TG cell function. (A) Specific 
targeted protein bands as detected by respective antibodies via Western blot. (B) Protein 
levels of P-PERK, PERK, and ratio of P-PERK: PERK at 6 hours. All arbitrary values were 
expressed as means normalized to Amido Black ± SEM. (C) mRNA levels of Pl-1, Pgf, 
and Hand1 after 24 hours. All arbitrary values were expressed as means normalized to 
either Amido Black ± SEM, or the geometric mean of β-Actin and Gapdh ± SEM. All 
experiments were performed in quadruplicates (n=4). Significant differences between 
treatment groups determined by one-way ANOVA (1WA) followed by Tukey’s post-test 
were indicated by * (p<0.05; significant difference from control) or ≠ (p<0.05; significant 
difference from nicotine).  
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Supplemental Figure 5. The effect of maternal nicotine exposure on miR-211 levels. 
Levels of miR-211 were determined via RT-PCR. miRNA levels were expressed as means 
normalized to RNU6B ± SEM (n=5-6/group). *, Significant difference (p<0.05). 
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separate from and independent of the terms and conditions of this Public License. 
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 Graduate Research Scholarship $4,500/year (2013-2015) 
 Physiology and Pharmacology Research Day Poster Presentation 1st place (2014) 
 Paul Harding Research Day Oral presentation 2nd place (2014) 
 Public Service Alliance of Canada Academic Achievement Scholarship $500 (2014) 
 Obstetrics and Gynaecology Graduate Scholarship $15,500/year (2013-14) 
 Dean's Honour List 5 years (2009-13) 
 Western’s Excellence in Leadership Award (2011) 
 Western Scholarship of Distinction $1,000 (2008-2009) 
 Harold Botsford Memorial Award $300 (2008) 
 Writer’s Craft Highest Graduating Average (2008) 
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PRESENTATIONS 
1. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Characterization of the endoplasmic 
reticulum stress response in nicotine-induced placental insufficiency. Oral presentation at Paul 
Harding Research Day, London ON, May 2015. 
2. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Characterization of the endoplasmic 
reticulum stress response in nicotine-induced placental insufficiency. Oral presentation at Southern 
Ontario Reproductive Biology Meeting, Hamilton ON, May 2015. 
3. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Characterization of the endoplasmic 
reticulum stress response in nicotine-induced placental insufficiency. Oral presentation at London 
Health Research Day, London ON, April 2015. 
4. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to impaired 
disulfide bond formation and endoplasmic reticulum stress in the rat placenta. Poster presentation at 
Society of Reproductive Investigation, San Francisco CA, March 2015. 
5. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Characterization of the endoplasmic 
reticulum stress response in nicotine-induced placental insufficiency. Oral presentation at Lawson 
Health Research Institute Talks on Fridays, London ON, February 2015. 
6. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to impaired 
disulfide bond formation and endoplasmic reticulum stress in the rat placenta. Poster presentation at 
Canadian National Perinatal Research Meeting, Montebello QC, February 2015. 
7. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to impaired 
disulfide bond formation and endoplasmic reticulum stress in the rat placenta. Poster presentation at 
Physiology and Pharmacology Research Day, London ON, November 2014. 
8. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to 
augmented endoplasmic reticulum stress in the rat placenta. Oral presentation at Paul Harding 
Research Day, London ON, May 2014. 
9. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to 
augmented endoplasmic reticulum stress in the rat placenta. Oral presentation at Southern Ontario 
Reproductive Biology Meeting, Toronto ON, April 2014. 
10. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Maternal nicotine exposure leads to 
augmented endoplasmic reticulum stress in the rat placenta. Poster presentation at London Health 
Research Day, London ON, March 2014. 
11. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Exposure to nicotine or low-protein diet in 
pregnancy leads to ER stress in the rat placenta. Poster presentation at Physiology and Pharmacology 
Research Day, London ON, November 2013. 
12. Wong M, Nicholson CJ, Holloway AC, and Hardy DB. Nicotine exposure in vitro leads to decreased 
expression of Tryptophan Hydroxylase 1 (TPH1) in pancreatic and placental cell lines. Poster 
presentation at Physiology Thesis Poster Day, London ON, March 2013. 
